Thank You to the 2011 ASHI Corporate Supporters!

Abbott Molecular
Art Robbins Instruments
Bio-Rad Laboratories
Conexio Genomics
Elsevier
GenDx
Gen-Probe
Histogenetics
Life Technologies
Linkage Biosciences, Inc.
MLC Group, LLC
National Marrow Donor Program
Olerup, Inc.
One Lambda, Inc.
Promega Corporation
Qiagen, Inc.
STEMCELL Technologies, Inc.
SystemLink, Inc.
Table of Contents

General Information ................................................................. 3
ASHI Program Planning Committee ............................................. 7
Abstract Reviewers ................................................................. 9
Board of Directors .................................................................... 15
Corporate Supporters .............................................................. 19
Exhibit Information ................................................................. 20
Award Winners ......................................................................... 32
Schedule at a Glance with Meeting Rooms................................. 43
Hotel & Exhibit Hall Floor Plans............................................... 106
General Information

Registration

Registration is located in the Grand Ballroom Foyer on the 5th Floor.

Monday, October 17                Noon – 7:00 PM
Tuesday, October 18                7:30 AM – 6:00 PM
Wednesday, October 19              7:30 AM – 6:00 PM
Thursday, October 20               7:30 AM – 6:00 PM
Friday, October 21                 7:30 AM – 10:00 AM

Speaker Ready Room

Speaker Ready Room is located in the Grand Chenier on the 5th Floor.

Monday, October 17                Noon – 7:00 PM
Tuesday, October 18                7:00 AM – 6:00 PM
Wednesday, October 19              7:00 AM – 6:00 PM
Thursday, October 20               7:00 AM – 6:00 PM
Friday, October 21                 7:00 AM – 10:00 AM

Exhibits/Internet Café

Exhibits are located in the Napoleon Ballroom on the 3rd Floor.

Hours and Poster Viewing
Tuesday, October 18                10:00 AM – 12:15 PM
                                        2:30 PM – 7:00 PM
Wednesday, October 19               10:00 AM – 12:15 PM
                                        2:30 PM – 6:00 PM
Thursday, October 20                10:30 AM – 12:30 PM

Poster Mounting Times:

Monday, October 17                  3:00 PM – 7:00 PM
Tuesday, October 18                  7:00 AM – 9:00 AM

Poster Dismounting Time:

Thursday, October 20                 Noon – 2:00 PM
General Information

**ADA Compliance**
ASHI fully complies with the legal requirements of the Americans with Disabilities Act rules and regulations. If any participant is in need of special accommodations please notify the hotel and indicate the type of assistance needed. ASHI cannot ensure the availability of appropriate assistance without advance notice.

**Cameras and Cell Phones**
No cameras of any kind are permitted inside education session rooms. Any violation of this policy may result in the offender being removed from the meeting. As a courtesy to fellow attendees, please turn off cell phones during educational sessions.

**Meeting Objectives**
The 37th Annual Meeting has been designed to provide participants with a comprehensive review of current issues in immunogenetics and histocompatibility. New morning sessions will introduce the daily session themes and will focus on evaluating the genetic variation of the HLA system at the population level and its role in predisposition and protection in autoimmune disorders and infections. The plenary and symposia sessions were designed to examine emerging technologies and the dichotomous roles of T and B lymphocytes in modulating immune responses and causing injury to allogeneic grafts. The scientific program will conclude with an overview of the state-of-the-art factors defining outcomes in hematopoietic stem cell transplantation and providing an update on changes in histocompatibility practices for solid organ transplantation.

The workshop sessions are complementary to the scientific program. Workshops were designed to provide a means to discuss relevant issues in HLA laboratory practices, standardization of HLA antibody assays and levels of typing resolution. Additionally, workshops illustrate methods for the analysis of the distribution of immunogenetics factors in populations and the variation in selection of donors for hematopoietic stem cell transplantation. Case studies provide the attendees with criteria for selection of donors for hematopoietic stem cell transplantation and presentations of clinical cases including challenges in laboratory practices.

After attending this meeting, participants should have a better understanding of immunoregulatory processes and mechanisms of tissue injury in allogeneic transplantation. Participants will receive state-of-the-art information regarding donor selection that will allow them to develop criteria for optimal utilization and interpretation of histocompatibility tests.
General Information

**Evaluation**
Participants must complete an evaluation form in order to receive a certificate documenting credits earned for attending sessions. Sessions must be attended in their entirety. Partial credit is not available. Following the meeting, complete the evaluation and print your certificate by visiting www.cmecertificateonline.com. Online meeting evaluations will be available from October 21 – November 21, 2011, after which time certificates will no longer be available.

**Physicians**
ASHI is accredited by the Accreditation Council of Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**AMA PRA Statement**
ASHI designates this education activity for a maximum of 34.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**CHT, CHS, ABHI Diplomates**
The American Board of Histocompatibility and Immunogenetics has approved the 37th Annual Meeting content for a maximum of 26.75 contact hours and 4.0125 continuing education credits (CEC); and has approved the Inspectors’ Training Workshop content for a maximum 7.5 contact hours and 1.125 CEC, applicable for Certified Histocompatibility Technologists (CHT), Certified Histocompatibility Specialists (CHS), and ABHI Diplomates.

**Abstract Awards**
The following awards will be presented to the highest ranked abstracts accepted for oral presentation: ASHI Scholars, International Scholar, Best Solid Organ Case Study and Best Stem Cell Case Study. Three posters will be awarded the following: President’s Choice, Best Visual and Most Innovative.

**Internet Café – Supported by Abbott Molecular**
Complimentary computer stations are provided enabling you to access the internet. The Internet Café is located in the Napoleon Ballroom on the 3rd Floor. Use of these computers is limited to 15 minutes.

**New – iPosters – Supported by Life Technologies**
Visual representation of poster abstracts on display in the Napoleon Ballroom are available for viewing by visiting the following URL ashi.posterview.com.
Hotel Information

**Louisiana Purchase Gift Shop, Lobby**
The gift shop features unique souvenirs and forgotten necessities. It is located near the elevator banks on the lobby level.
**Hours:** 7:00 AM – 10:00 PM daily

**Pelican Bar, Lobby**
Named in honor of Louisiana’s most visible symbol and state bird, the Pelican Bar is reminiscent of a French Quarter courtyard with its magnificent tiered fountain, lavish landscaping and hand detailed wrought iron. Relax in its casual atmosphere with your favorite libation, meet and mingle with a signature New Orleans cocktail, enjoy a splendid selection from the light fare menu or cap off your evening in grand style. Unwind and embrace the ambiance of New Orleans in the Pelican Bar.
**Hours:** Monday – Friday 11:00 AM – Closing  
Saturday/Sunday 10:00 AM - Closing

**Starbucks, Lobby**
The Pacific Northwest meets the Big Easy at the Starbucks Coffee Store. Treat yourself to coffees from around the world, espresso beverages, tasty baked goods and selected merchandise. Or enjoy a light lunch with a selection from our crisp salads and deli-style sandwiches in an atmosphere suited for business or pleasure.
**Hours:** 5:30 AM – 5:00 PM daily

**Roux Bistro, 2nd Floor**
The roux is the foundation of Creole and Cajun cooking and the premiere ingredient of New Orleans’ most famous dishes. In honor of this culinary tradition, the Sheraton New Orleans Hotel has named its restaurant Roux Bistro. Serving breakfast and lunch daily, the Bistro allows you to savor contemporary cuisine with a Creole flair and have a memorable meal without having to leave the hotel.
**Hours:** Breakfast 6:30 AM - 11:00 AM • Lunch 11:00 AM – 2:00 PM

**Business Center, 4th floor**
A full service Business Center with fax services, copying services, computers and high speed Internet access is located on the fourth floor as soon as you get off the escalators. The Business Center receives packages, faxes and messages.
**Hours:** Monday – Friday 7:00 AM – 6:00 PM  
Saturday/Sunday 8:00 AM – 4:00 PM
Hotel Information

**Emergency**
In case of emergency, dial 0 for the operator from any house phone.

**Lost & Found**
Items left in meeting rooms will be turned in to hotel security. Dial extension 6256 from any house phone to inquire about lost items.

**ASHI Program Planning Committee**

**Program Planning Chair**
Marcelo Fernández-Viña, PhD, D(ABHI)
*Stanford University School of Medicine*

**Plenary and Symposium Sessions**
Nebila Abdulwahab, MT(ASCP),CHT
*Ohio State University Hospital*

Lee Ann Baxter-Lowe, PhD, D(ABHI)
*University of California San Francisco*

Robert Bray, PhD, D(ABHI)
*Emory University Hospital*

Daniel Cook, PhD, D(ABHI)
*UT Houston Health Science Center*

Deborah Crowe, PhD, D(ABHI)
*DCI Laboratory*

Henry Erlich, PhD
*Roche Molecular Systems*

William Hildebrand, PhD, D(ABHI)
*University of Oklahoma Health Science Center*

Geoffrey Land, PhD, HCLD
*The Methodist Hospital Weill Cornell Medical College*

Mayra Lopez-Cepero, PhD, D(ABHI)
*LifeLink Foundation*
ASHI Program Planning Committee

Martin Maiers  
National Marrow Donor Program

Harriet Noreen, BS, CHS  
Fairview University Medical Center

David Partlow, MS, MT, CHS  
MD Anderson Cancer Center

Elaine Reed, PhD, D(ABHI)  
UCLA Immunogenetics Center

Nancy Reinsmoen, PhD, D(ABHI)  
Cedars-Sinai Medical Center

Sandra Rosen-Bronson, PhD, D(ABHI)  
Georgetown University Hospital

Dean Sylvaria, CHS  
Beth Israel Deaconess Medical Center

Victoria Turner, PhD, D(ABHI)  
St. Jude’s Children’s Research Hospital

Dolly Tyan, PhD, D(ABHI)  
Stanford University

Adriana Zeevi, PhD, D(ABHI)  
University of Pittsburgh Medical Center

Abstract Chairs

Patricia Campbell, MBChB, MRCP(UK), F  
University of Alberta Hospitals

Sallyanne Fossey, PhD, D(ABHI)  
DCI Laboratory

Shalini Pereira, PhD, D(ABHI)  
Seattle Cancer Care Alliance
ASHI Program Committee

Workshop Chairs
John M. Hart, MBA, CHS
Johns Hopkins University

Walter Herczyk, MT(ASCP), CHS
University of Chicago Medical Center

Continuing Medical Education Accreditation Manager
Jillian Davis
SmithBucklin Corporation

ASHI Abstract Reviewers

Moheeb Al-Awwami, PhD, CHT, CHS
King Faisal Specialist Hospital and Research Center

Medhat Askar, MD, PhD, D(ABHI)
Allogen Laboratories

Lee Ann Baxter-Lowe, PhD, D(ABHI)
University of California San Francisco

Noureddine Berka, PhD, D(ABHI)
Calgary Laboratory Services

Maria Bettinotti, PhD, D(ABHI)
Quest Diagnostics Nichols Institute

Rainer Blasczyk, MD, PhD
Hannover Medical School

Benita Book, CHT, CHS
Indiana University

Patricia Campbell, MBChB, MRCP(UK), F
University of Alberta Hospitals

Pam Chapman, MT (ASCP)
Emory University Hospital

James Cicciarelli, PhD
National Institute of Transplantation
ASHI Abstract Reviewers

Frans Claas, PhD
Leiden University Medical Center

Daniel Cook, PhD, D(ABHI)
UT Houston Health Science Center

Deborah Crowe, PhD, D(ABHI)
DCI Laboratory

Steven DeGoey, BS, CHS
Mayo Clinic

Julio Delgado, MD, MS, D(ABHI)
University of Utah

Nicholas DiPaola, PhD
Ohio State University Medical Center

Ronald Domen, MD
Penn State Milton S. Hershey Medical Center

Ilias Doxiadis, PhD
Leiden University Medical Center

Thomas Ellis, PhD, D(ABHI)
Blood Center Southeast Wisconsin

Sallyanne Fossey, PhD, D(ABHI)
DCI Laboratory

Manish Gandhi, MD
Mayo Clinic

Maria Gerbase-De Lima, MD, PhD
Federal University of San Paulo

Alin Girnita, MD, D(ABHI)
University of Cincinnati Academic Health Center

David Gjertson, PhD
University of California Los Angeles
ASHI Abstract Reviewers

Clara Gorodezky, DSc, PhD
INDRE

Greg Hadley, PhD
Ohio State University

Amy Hahn, PhD, D(ABHI)
Albany Medical College

Gregory Hale, MD
All Children’s Hospital

Vera Hauptfeld-Dolejsek, PhD, D(ABHI)
University of Alabama at Birmingham

Sandra Helman, PhD, D(ABHI)
Georgia Health Sciences University

William Hildebrand, PhD, D(ABHI)
University of Oklahoma Health Science Center

Susan Hsu, PhD
American Red Cross Blood Services

Charlene Hubbell, BS, MT(ASCP), SBB
SUNY Upstate Medical University

Malek Kamoun, MD, PhD
University of Pennsylvania

Siva Kanangat, PhD
Rush University Medical Center

Ronald Kerman, PhD
University of Texas Medical School

Pamela Kimball, PhD, HCLD
Medical College of Virginia

William Klitz, PhD
University of California
ASHI Abstract Reviewers

Ellen Klohe, PhD, D(ABHI)
*Inland Northwest Blood Center*

Chantal Lacelle, MD, PhD
*UT Southwest Medical Center*

Peter Lalli, PhD
*Allogen Laboratories*

Jar-How Lee, PhD, D(ABHI)
*One Lambda, Inc.*

Curt Lind, CHS
*Children’s Hospital of Philadelphia Immunogenetics Laboratory*

Mayra Lopez-Cepero, PhD, D(ABHI)
*LifeLink Foundation*

Steven Mack, PhD
*Childrens Hospital Oakland*

Susana Marino, MD, PhD, D(ABHI)
*University of Chicago Hospital Medical Center*

James Mathew, PhD
*Northwestern University Feinberg School of Medicine*

Narinder Mehra, PhD
*All-India Institute of Medical Sciences*

Derek Middleton, DSc, PhD, FRC
*Royal Liverpool University Hospital*

Joshua Miller, MD
*Northwest University Feinberg School of Medicine*

Thalachallour Mohanakumar, PhD, D(ABHI)
*William Beaumont Hospital*

Dimitri Monos, PhD
*University of Pennsylvania/Children’s Hospital of Philadelphia*
ASHI Abstract Reviewers

Gerald Morris, MD, PhD
Washington University School of Medicine

Karen Nelson, PhD, D(ABHI)
Puget Sound Blood Center

Peter Nickerson, MD, FRCPC
Canadian Blood Services

Allen Norin, PhD, D(ABHI)
SUNY Downstate Medical Center

Paul Norman, PhD
Stanford University

Carol Pancoska, PhD, D(ABHI)
Community Blood Services

Marcelo Pando, PhD, D(ABHI)
Stanford University

Shalini Pereira, PhD, D(ABHI)
Fred Hutchinson Cancer Research Center

Donna Phelan, BA, CHS, MT(HEW)
Barnes-Jewish Hospital

Michele Prod, BS, MT(ASCP), CHS
Rush University Medical Center

Lucie Richard, PhD
Hema-Quebec

Jerry Rosenberg, MD, PhD
Gift of Life Michigan

Susan Saidman, PhD, D(ABHI)
Massachusetts General Hospital

Jennifer Schiller, PhD
Blood Center of Wisconsin
ASHI Abstract Reviewers

David Senitzer, PhD, D(ABHI), ABMLI
City of Hope Medical Center

Hiroko Shike, MD
Penn State Hershey Medical Center

Ruby Siegel, MS, CHS
Inland Northwest Blood Center

Anajane Smith, MA
Seattle Cancer Care Alliance

Peter Stastny, MD
University of Texas Southwestern Medical Center

Brian Susskind, PhD, MS, BA, D(ABHI)
Baylor University Medical Center

Anat Tambur, DMD, PhD, D(ABHI)
Northwestern University

Gary Teresi, MT, CHS
Allogen Laboratories

Marcel Tilanus, PhD
University Hospital Maastricht Tissue Typing Laboratory

Kathryn Tinckam, MD
University Health Network

Elizabeth Trachtenberg, MS, PhD, D(ABHI)
Children’s Hospital & Research Center at Oakland

Victoria Turner, PhD, D(ABHI)
St. Jude Children’s Research Hospital

Carlos Vilches, PhD
Puerta de Hierro Hospital
2011 Board of Directors

2011 Executive Committee

President
Geoffrey Land, PhD, HCLD (2011)
The Methodist Hospital
Weill Cornell Medical College
HLA & Transplant Immunology
6565 Fannin Street B280
Houston, TX 77030
Phone: (713) 441-0424 · Fax: (713) 441-0489
gland@tmhs.org

President Elect
Amy B. Hahn, PhD, D(ABHI) (2011)
Albany Medical College
Transplant Immunology Laboratory, MC 122
47 New Scotland Avenue
Albany, NY 12208
Phone: (518) 262-5574 · Fax: (518) 262-6274
hahna@mail.amc.edu

Past President
Marcelo Fernández-Viña, PhD, D(ABHI) (2011)
Stanford University School of Medicine
Department of Pathology/Blood Center
3373 Hillview Avenue
Palo Alto, CA 94304
Phone: (650) 723-7968 · Fax: (650) 725-4470
marcelof@stanford.edu

Vice President of Operations
John Hart, MBA, CHS (2011)
Johns Hopkins University
Immunogenetics Laboratory
2041 East Monument Street
Baltimore, MD 21205
Phone: (410) 955-3600 x105 · Fax: (410) 955-0431
hartjm@jhmi.edu
2011 Board of Directors

2011 Executive Committee

Secretary
Dorothy M. Levis, MT(ASCP), CHS(ABHI) (2013)
Gift of Life Michigan
3861 Research Park Drive
Ann Arbor, MI 48108
Phone: (734) 922-1056 · Fax: (734) 973-0332
dlevis@giftoflifemichigan.org

Treasurer
Doreen A. Jezek, MS, CHS, CLSP(MB) (2012)
University of Kentucky
ImmunoMolecular Pathology Laboratory
800 Rose Street, HA629
Lexington, KY 40536
Phone: (859) 257-4583 · Fax: (859) 257-0029
dajeze0@email.uky.edu
2011 Board of Directors

2011 Board of Directors

Lee Ann Baxter-Lowe, PhD, D(ABHI)
University of California San Francisco
Box 0508
Immunogenetics & Transplant Laboratory
San Francisco, CA 94143-0508
Phone: (415) 476-3883
LeeAnn.BaxterLowe@ucsfmedctr.org

Maria Bettinotti, PhD, D(ABHI) (2013)
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
HLA and Immunogenetics
Chantilly, VA 20151
Phone: (703) 802-7254
maria.p.bettinotti@questdiagnostics.com

John A. Gerlach, PhD, D(ABHI)
Michigan State University
B228 Life Science Building
East Lansing, MI 48824-1317
Phone: (517) 432-3467
gerlach@msu.edu

Joannis Mytilineos, MD, PhD
Und Immungenetik (IKT) GGmbH
Leiter Der Abt
Transplantations Immunologist
Helmholtzstrabe 10
D-89081 ULM – GERMANY
Phone: 49-731-150-524
j.mytilineos@blutspende.de

Diana J. Pidwell, PhD, MT(ASCP), D(ABHI)
Allegheny General Hospital
320 East North Avenue
Pittsburgh, PA 15212
Phone: (502) 608-0097
mamasquare.pidwell@gmail.com
2011 Board of Directors

2011 Board of Directors
Karen L. Pierce, CHS(ABHI)
Blood Center of Wisconsin
638 North 18th Street
Milwaukee, WI 53233
Phone: (414) 937-6262
karen.pierce@bcw.edu

Elizabeth R. Trimble, MT(ASCP), CHS(ABHI)
Via Christi Regional Medical Center
#3653 929 North St Francis
HLA Laboratory
Wichita, KS 67214
Phone: (316) 268-5447
Elizabeth_Trimble@via-christi.org
Corporate Supporters

**Diamond Level**
Life Technologies
(iPosters)

One Lambda, Inc.
(Unrestricted Educational Grant)

**Platinum Level**
Abbott Molecular
(Internet Café)

Gen-Probe
(Final Program Printing)

**Gold Level**
Histogenetics
(Registration Bags)

**Silver Level**
GenDx
(Poster Reception)

Olerup, Inc.
(Water Bottles)

**Bronze Level**
Bio-Rad Laboratories
(Distinguished Scientist Award)

Conexio Genomics
(Notepads & Pens)

Elsevier
(International Scholar Award)

National Marrow Donor Program
(Outstanding Technologist Award)

Art Robbins Instruments
(Plenary III: Emerging Technologies)

Linkage Biosciences, Inc.
(Distinguished Service Award)

Promega Corporation
(ASHI Scholar Award)

Qiagen, Inc.
(ASHI Scholar Award)

STEMCELL Technologies, Inc.
(ASHI Scholar Award)

Friends of ASHI

MLC Group, LLC
(Outstanding Technologist Dinner)

SystemLink, Inc.
# Exhibit Information

## Exhibitor Booth Numbers

<table>
<thead>
<tr>
<th>Name</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Molecular</td>
<td>601</td>
</tr>
<tr>
<td>Accurate Chemical &amp; Scientific Corporation</td>
<td>704</td>
</tr>
<tr>
<td>Adaptive TCR Corporation</td>
<td>307</td>
</tr>
<tr>
<td>American Foundation for Donation &amp; Transplantation</td>
<td>105</td>
</tr>
<tr>
<td>BIOplastics CYCLERtest Inc.</td>
<td>103</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>406</td>
</tr>
<tr>
<td>CEDARLANE</td>
<td>106</td>
</tr>
<tr>
<td>Cylex</td>
<td>206</td>
</tr>
<tr>
<td>DNA Genotek</td>
<td>100</td>
</tr>
<tr>
<td>Embi Tec</td>
<td>705</td>
</tr>
<tr>
<td>Gen-Probe</td>
<td>201</td>
</tr>
<tr>
<td>GenTrak, Inc.</td>
<td>107</td>
</tr>
<tr>
<td>Histogenetics</td>
<td>501</td>
</tr>
<tr>
<td>LabCorp</td>
<td>701</td>
</tr>
<tr>
<td>Life Technologies</td>
<td>301</td>
</tr>
<tr>
<td>Linkage Biosciences, Inc.</td>
<td>706</td>
</tr>
<tr>
<td>NicheVision Biosciences, LLC</td>
<td>207</td>
</tr>
<tr>
<td>NorDiag</td>
<td>703</td>
</tr>
<tr>
<td>Olerup, Inc.</td>
<td>306</td>
</tr>
<tr>
<td>One Lambda, Inc.</td>
<td>401</td>
</tr>
<tr>
<td>Path-Tec</td>
<td>104</td>
</tr>
<tr>
<td>PerkinElmer</td>
<td>603</td>
</tr>
<tr>
<td>Promega Corporation</td>
<td>605</td>
</tr>
<tr>
<td>PROTRANS</td>
<td>707</td>
</tr>
<tr>
<td>Qiagen, Inc.</td>
<td>200</td>
</tr>
<tr>
<td>Roche-454 Sequencing</td>
<td>102</td>
</tr>
<tr>
<td>ROSE Europe GmbH</td>
<td>309</td>
</tr>
<tr>
<td>SoftGenetics, LLC</td>
<td>702</td>
</tr>
<tr>
<td>STEMCELL Technologies, Inc.</td>
<td>101</td>
</tr>
<tr>
<td>SystemLink, Inc.</td>
<td>202</td>
</tr>
<tr>
<td>Trans-Type Diagnostics</td>
<td>209</td>
</tr>
</tbody>
</table>
Exhibitor Company Descriptions

Abbott Molecular ............................................................................... 601
1300 Touhy Avenue
Des Plaines, IL 60154
Phone: (224) 361-7823
www.abbottmolecular.com

Abbott Molecular, is an emerging leader in molecular diagnostics – the analysis of DNA, RNA, and proteins at the molecular level. Abbott Molecular’s instruments and reagents detect pathogens and subtle key changes in patients’ genes and chromosomes, which can aid in earlier diagnoses, selection of appropriate therapies and monitoring of disease recurrence.

Accurate Chemical & Scientific Corporation ............................... 704
300 Shames Drive
Westbury, NY 11590
Phone: (516) 333-2221
www.accuratechemical.com

Optiprep, Lymphoprep isolation Media, Euro-Diagnostica Plasmodipur Blood Filters, Biocidal-2F & AquaClean Lab Disinfectants, Electro-elution, dialysis & gel extraction with GeBA tools, Unisep whole blood separation vials, HeLA Cells, collagen assay, Apoptosis kits, HLA antisera, standard, low-tox complements, antibodies - isolation of cells, viruses, organelles with T-cells recovery columns, chick embryo extract.

Adaptive TCR Corporation ..................................................... 307
307 Westlake Avenue North
Suite 300
Seattle, WA 98109
Phone: (206) 659-0067
www.adaptivetcr.com

Adaptive’s TCR Profiling service provides a biochemical method for parallel sequencing millions of TCRs with the data analysis capability of a secure proprietary relational database management system. Adaptive’s immunoSEQ system combines the capabilities of ultrahigh-throughput DNA sequencing with a proprietary sequencing methodology and a powerful bioinformatics software suite to provide exceptionally deep access to T Cell repertoires.
Exhibitor Company Descriptions

American Foundation for Donation & Transplantation ............ 105
8154 Forest Hill Avenue
Suite 3
Richmond, VA 23235
Phone: (804) 323-9890
www.amfdt.org

The American Foundation for Donation & Transplantation, formerly SEOPF, is the continuation of the oldest transplantation and donation professional organization in the United States. Founded in 1969 in Richmond, Virginia by Drs. David Hume and Bernard Amos, SEOPF gave rise to UNOS and now has become the AFDT. www.amfdt.org, 1(800)-KIDNEY9.

BIOplastics/CYCLERtest Inc. ..................................................... 103
2933 South Miami Boulevard
Suite 121
Durham, NC 27703
Phone: (919) 806-8811
www.bpcti.com

BIOplastics/CYCLERtest Inc. is positioned to assist with two key variables in (q) PCR, thermal cyclers and plastic vessels. DRIFTCON dynamic multi-channel temperature validation systems (calibrated in ISO 17025 Standards) meet most accreditation requirements for PCR temperature validation, and together with our Extreme Uniformity plastic disposables help provide consistent and reproducible results.

Bio-Rad Laboratories ................................................................. 406
4000 Alfred Nobel Drive
Hercules, CA 94547
Phone: (510) 741-4019
www.bio-rad.com

Bio-Rad offers a complete line of industry standard HLA Serology Typing Trays (Lymphotype); Serological (Lymphoscreen) and ELISA-based (AbScreen/AbIdent) Antibody Diagnostics Systems; Molecular Typing Systems (SSO and SSP) with full automation platforms; Immune Monitoring, Infectious Disease, and Traditional Blood Group Serology Products to meet your laboratory needs.
Exhibitor Company Descriptions

CEDARLANE ............................................................................. 106
4410 Paletta Court
Burlington, ON L7L 5R2
Phone: (800) 268-5058
www.cedarlanelabs.com

CEDARLANE® (ISO 9001, ISO 13485 registered) specializes in providing high quality research & diagnostic reagents to the life science community. We offer one of the most extensive product listings in the world both domestically & internationally. Delivering Today’s Innovations for the Science of Tomorrow™

Cylex .......................................................................................... 206
8980-I Old Annapolis Road
Columbia, MD 21045
Phone: (410) 964-0236
www.cylex.net

Cylex is a life sciences company which develops and commercializes in vitro diagnostic products that illuminate immunity. Its patented technology provides an innovative platform to assess immune cell function - providing insight for individualized patient management. ImmuKnow®, the Company’s FDA-cleared product, is used to manage and optimize immunosuppression in transplant patients.

DNA Genotek ............................................................................. 100
2 Beaverbrook Road
Ottawa, ON K2K 1L1
Phone: (613) 723-5757
www.dnagenotek.com

DNA Genotek is focused on improving nucleic acid sample collection. The company’s Oragene® product line offers registries and researchers a non-invasive, all-in-one system for the collection, stabilization, transportation and purification of high quality DNA from saliva. Oragene’s reliability and ease-of-use have resulted in rapid worldwide adoption by top-tier registries and health institutions.
Embi Tec manufactures and distributes innovative, cost and space effective lab equipment such as the RunOne Electrophoresis System, MultiCaster Systems, ViewOne LabLite (miniature white light box), LightOne Illuminators for setting up and cherry-picking 96 or 384-well plates, PrepOne Sapphire (non-UV, blue light box), PrepOne ImageCatcher and EzWay Direct PCR Buffers.

Gen-Probe is a global leader in molecular diagnostics for infectious disease, transplant diagnostics, oncology and blood screening. The LIFECODES® product line includes immunodiagnostic and genotyping assays used to determine Human Leukocyte Antigens (HLA) and detect alloantibodies to donor antigens that may cause unwanted immune responses in transplant or transfusion recipients.

GenTrak, Inc. manufactures a quality line of classical HLA serology trays and Frozen Cell trays. HLA serology testing provides quick, cost effective results as well as useful information for molecular typing. When used in conjunction with molecular products, serological typing helps resolve ambiguities and null alleles. Please come see our SSP products, including Cycler check, Wipetest and our unique ABCDRDQ divided well design providing 192 reactions on 1 tray.
Exhibitor Company Descriptions

**Histogenetics .......................................................... 501**
300 Executive Boulevard
Ossining, NY 10567
Phone: (914) 762-0300
www.histogenetics.com

Histogenetics, based in New York, USA, is an international leader in DNA sequence-based tissue typing (SBT) services and serves clients around the globe. Histogenetics has been developing sophisticated tools by integrating robotics and bio-informatics to provide affordable and the ultimate quality of HLA typing information to the community that could save lives.

**LabCorp ................................................................. 701**
1440 York Court Extension
Burlington, NC 27215
Phone: (336) 436-7301
www.labcorp.com

LabCorp is global leader in providing Human Leukocyte Antigen (HLA) typing services for transplant centers, bone marrow donor registries and cord blood banks worldwide. Specializing in Sequence Based Typing (SBT), our PhD scientists and laboratory technicians have provided over 2 million individual HLA typings for both Class I and Class II antigens using highly robust molecular methods.

**Life Technologies ................................................... 301**
5791 Van Allen Way
Carlsbad, CA 92008
Phone: (760) 603-7200
www.lifetechnologies.com

Life Technologies is a global biotechnology tools company dedicated to improving the human condition. Our customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. For information on how we are making a difference, visit: www.lifetechnologies.com.
Exhibitor Company Descriptions

**Linkage Biosciences, Inc.** ................................................................. 706
2503 Bush Street
San Francisco, CA 94115
Phone: (866) 575-8915
www.linkagebio.com

Linkage Biosciences is a molecular diagnostics company focused on products for hematopoietic stem cell and solid organ transplantation. LinkSeq™ is the world’s first HLA typing product using real-time PCR - no more electrophoresis or probing. Save time and increase laboratory productivity. Come learn more about this exciting new technology.

**NicheVision Biosciences, LLC**..................................................... 207
526 South Main Street
Suite 7146
Akron, OH 44311
Phone: (330) 252-2711
www.nichevision.com

NicheVision Biosciences, LLC develops software to streamline DNA interpretation and reporting. ChimeraHD™ is software (developed with United States Army) to assist transplant centers more effectively and efficiently monitor bone marrow post-transplant patient progress including determination of informative alleles, calculations for percent chimerism by loci, and preparation of final report.

**NorDiag** ................................................................................. 703
1000 Mansell Exchange West
Suite 305
Alpharetta, GA 30022
Phone: (678) 205-8880
www.NorDiag.com

NorDiag is a molecular diagnostics company which has developed a novel pre-analytic platform which is capable of nucleic acid extraction and cell separation. This 2-in-1 instrument is ideally suited to the HLA and Molecular Genetic laboratory market where cost effective DNA preparation and cell separation can be performed with walk away automation. Using established paramagnetic bead chemistry, the Arrow instrument can deplete or enrich a subset of PBMC’s based upon end users specifications. For more information visit us at http://www.nordiag.com.
Exhibitor Company Descriptions

Olerup, Inc. ................................................................. 306
901 S Bolmar Street
Suite R
West Chester, PA 19382
Phone: (877) 653-7871
www.olerup.com

Olerup is a life science company with a focus on transplantation that provides high quality products and services, in order to facilitate safe and effective bone marrow and solid organ transplants. Olerup is the global distributor of innovative molecular diagnostic products and services for transplantation: HLA typing (Olerup SSP® and SBT Resolver™) and for non-HLA antibody detection (XM-ONE®). Olerup's product offerings are distributed through Olerup, Inc. (Americas) and Olerup GmbH (Rest of World).

One Lambda, Inc. ......................................................... 401
21001 Kittridge Street
Canoga Park, CA 91303
Phone: (818) 702-0042
www.onelambda.com

Booth 401 is the place to be. Don’t miss our newest products - HNA3 Genotyping tray and ConsenSys™ SBT - and see the full capabilities of LABXpress™ for automated assay processing. Also featured are our premier products, LABScreen® Single Antigen and Cq1Screen™, ideal for identifying DSA, and LABType® HD for high resolution typing. And, be sure to join us on Wednesday, October 19, to party into the night at Generations Hall.

Path-Tec ............................................................... 104
1333-A Belfast Avenue
Columbus, GA 31904
Phone: (706) 569-6368
www.path-tec.com

Path-Tec is a leading provider of specimen management solutions that include kit design, production, distribution, tracking and inventory management. Our Lab Supplyline specimen management system gives laboratories the capability to order, track and auto-replenish inventory levels at the client level.
Exhibitor Company Descriptions

**PerkinElmer** ................................................................. 603
940 Winter Street
Waltham, MA 02451
Phone: (781) 663-6071
www.perkinelmer.com

PerkinElmer/formerly Chemagen USA, Inc.

**Promega Corporation** ....................................................... 605
2800 Woods Hollow Road
Madison, WI 53711
Phone: (608) 298-4842
www.promega.com

Promega Corporation develops optimized instruments and reagents for clinical research, molecular diagnostics, and HLA laboratories. The Maxwell® 16 automated nucleic extraction system provides consistent, reliable DNA for use in a wide range of downstream assays. The new Maxwell® 16 Buccal Swab DNA Purification Kit delivers high yield DNA from a non-invasive collection method. In addition to extraction technologies, we also offer options for nucleic acid quantitation and amplification reagents. Stop by Booth #605 to learn more about our workflow solutions.

**PROTRANS** ................................................................. 707
Ketschau 2
Hockenheim, Germany D68766
Phone: +49 6205 2929 9-0
www.protrans.info

PROTRANS is a company for research, development and production of diagnostic products for organ and bone marrow transplantation.
Exhibitor Company Descriptions

**Qiagen, Inc.**
19300 Germantown Road
Germantown, MD 20874
Phone: (240) 686-7688
www.qiagen.com

Over 500 proprietary, consumable products and automated/instrumentation solutions for sample collection, nucleic acid and protein handling, separation purification and detection. QIAGEN provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes like forensics, animal or food testing and pharmaceutical process control.

**Roche-454 Sequencing**
15 Commercial Street
Branford, CT 06405
Phone: (203) 871-2218
www.454.com

Roche develops and commercializes the innovative GS Junior and GS FLX Systems for high-throughput DNA sequencing. The hallmark of 454 Sequencing Systems are the high-quality, long reads which are well suited for a wide variety of applications including de novo sequencing, targeted region sequencing (i.e HLA genotyping), metagenomics and RNA analysis and more.

**ROSE Europe GmbH**
Industriepark Hoechst G830
Frankfurt am Main, Hessen 65929
Germany
Phone: +49(0)695 700 2800
www.rose-europe.de

ROSE Europe is a specialist manufacturer and supplier of HLA in-vitro tissue typing diagnostic kits. All of our manufacturing is undertaken in Frankfurt, Germany. We are compliant with and hold ISO 13485:2003 and ISO 9001:2000 Certificates. Our kits are manufactured to GMP standards and we hold all the relevant CE Certificates which assure the quality of the kit systems. Find out more about our organisation and range of products by visiting us on the stand. Alternatively contact us at www.rose-europe.de
Exhibitor Company Descriptions

SoftGenetics, LLC ............................................................................. 702
100 Oakwood Avenue
Suite 350
State College, PA 16803
Phone: (814) 237-9340
www.softgenetics.com

Featuring ChimerMarker™, automatic Chimerism analysis and monitoring software; NextGENe® software for analysis of all NGS data including the new, Rare Disease Detection Tool for both analyst and geneticists use; GeneMarker® software for MLPA®, Trisomy, AmplideX™ FMR1 chemistry, CF kits; MSI, LOH analysis and Mutation Surveyor® for analysis of Sanger Sequencing.

STEMCELL Technologies, Inc. ............................................................. 101
570 West 7th Avenue
Suite 400
Vancouver, BC V5Z 1B3
Phone: (800) 667-0322
www.stemcell.com

STEMCELL Technologies provides optimized cell separation products and systems for HLA and chimerism analysis, to facilitate high-volume sample processing and clear, reliable test results. EasySep™ and RosetteSep™ are fast, gentle, and can be used at room temperature. RoboSep™, the fully automated cell separator, isolates cells with no cross-contamination.
Exhibitor Company Descriptions

SystemLink, Inc. .............................................................................................................. 202
23475 Rock Haven Way
Suite 140
Dulles, VA 20166
Phone: (703) 651-5706
www.histotrac.com

Visit the SystemLink booth to learn about building a complete, customizable HLA laboratory management system to meet the needs of your laboratory. HistoTrac is a seamless system with flexible design, providing functionality to make data entry and data access quick and easy. Integrate with your testing analysis software and with your HIS/LIS. Share data with UNOS and NMDP. Use client reports designed to your specifications. Access your data from wherever you are. See the HistoTrac software for yourself - in the exhibit hall or in your office.

Trans-Type Diagnostics .............................................................. 209
108 Byte Drive
Suite 101
Frederick, MD 21702
Phone: (301) 695-7087

Trans-Type Diagnostics provides HLA serological test kits for immunogenetics laboratories throughout the world. Our products are backed by decades of experience and offer consistent results with comprehensive antigen coverage. Visit our booth, meet our staff and learn how we can be a valuable resource to your laboratory.
The Paul I. Terasaki Clinical Science Award was established in 2003 to honor an individual, group, or institution in recognition of significant accomplishments and/or contributions to the fields of clinical transplantation, histocompatibility and immunogenetics. This award was made possible by a grant from the Paul I. Terasaki Foundation.

The winner of the 2011 Paul I. Terasaki Clinical Science Award is:

Mark D. Stegall, MD
Mayo Clinic

Mark D. Stegall was born in Lubbock, Texas and grew up in West Texas. After graduating from high school, he attended Harvard College where he wrote for the student newspaper, The Crimson. During college, he worked two summers at the Rockefeller University in New York City, where he developed an interest in research and immunology. After college, he spent part of a year at a creative writing workshop at St John’s College, Oxford and the rest teaching chemistry in a high school outside Boston. He attended medical school at Columbia University College of Physicians and Surgeons in New York City with the goal of becoming a transplant surgeon. He stayed on as a surgical resident at Columbia’s Presbyterian Hospital spending two years in the research laboratory of Dr. Mark Hardy. He then did his transplant fellowship at the University of Wisconsin, Madison, under Dr. Folkert Belzer.

Dr. Stegall’s first faculty position was at the University of Colorado Medical Center in Denver where he started a pancreas transplant program and continued his research interest in the immunology of islet transplantation. After 5 years, he was recruited to become program director of the Kidney and Pancreas Transplant programs at the Mayo Clinic in Rochester, MN where he remains today. He is Professor of Surgery and Director of the Transplantation Immunology Laboratory at Mayo. His major research interests are in overcoming antibody barriers to transplantation and efforts to improve long-term graft survival using protocol biopsies and genomics. Both efforts are funded by the NIH.

Dr. Stegall is married and has one daughter who is a college sophomore. His major interest outside work is running and other endurance sports.
The Rose Payne Award

The Rose Payne Award was established in 1984 to honor a great scientist and to recognize her longstanding contributions to the field of immunogenetics. As a founding member, Dr. Rose Payne was always willing to share her knowledge and assist others in their endeavors. For more than 30 years, Dr. Payne made significant contributions in areas related to HLA. The Rose Payne Award was established as a tangible recognition of the high regard in which she was held.

The winner of the 2011 Rose Payne Award is:

Kathryn Wood, DPhil, FMedSci
University of Oxford

Kathryn Wood is Professor of Immunology in the Nuffield Department of Surgical Sciences, University of Oxford where she runs the Transplantation Research Immunology Group (TRIG – www.nds.ox.ac.uk/trig). Her research focuses on transplantation, particularly immune regulation and tolerance induction at the molecular and cellular level and interactions between the immune system and stem cells and stem cell derived tissues. She is a Fellow of The Academy of Medical Sciences and recently received a Royal Society Wolfson Merit Award for research excellence. Professor Wood’s professional activities include a broad array of responsibilities both nationally and internationally. She was President of The Transplantation Society (International) and is an editor of “Transplantation”.
The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunobiology.

The winner of the 2011 Distinguished Scientist Award is:

Mary S. Leffell, PhD, D(ABMLI), D(ABHI)
Johns Hopkins University School of Medicine
(Award Supported by Bio-Rad Laboratories)

Mary S. (Susie) Leffell, Ph.D., is Professor of Medicine and Co-director of the Immunogenetics Laboratory of the Johns Hopkins University School of Medicine. Dr. Leffell has been an active participant in clinical histocompatibility and transplantation for over thirty years. Trained as a clinical immunologist, her research focus before her involvement in transplantation was on congenital immunodeficiencies. Once exposed to transplantation, her research interests shifted to immunogenetics and transplantation immunology. She has directed studies of the distribution of HLA alleles and haplotypes among various racial/ethnic groups in the U.S. including Mexicans, Cubans, Puerto Ricans, Y’upik Eskimos, and Lakota Sioux. In collaboration with Dr. Andrea Zachary, her studies of HLA frequencies among the major ethnic groups in the national OPTN/UNOS registry established the diverse phenotype heterogeneity of African Americans compared to other groups and provided the basis for establishment of the calculated PRA in national organ allocation. Other immunogenetics studies investigated minor histocompatibility antigens, KIR, and cytokine alleles. In transplantation immunology, interest in humoral sensitization led to studies clearly establishing the impact of inflammation and infection among sensitized solid organ transplant candidates, as well as post-transplant sensitization following mismatched allogeneic hematopoietic cell transplantation (HCT). More recently, her focus has been on the role of HLA disparity and KIR mismatches on outcomes of nonmyeloablative non-myeloablative HCT, as well as desensitization for HCT candidates with donor specific HLA antibodies. She has contributed to the field through her involvement in ASHI and other professional societies, including the Transplantation Society and the American Society of Transplantation. She has served ASHI in several capacities: Chair of the Accreditation Committee, liaison to the Centers for Medicare/Medicare Aid Services (CMS), Councilor, Vice President, and President of the Society. She received ASHI’s Distinguished Service Award in 2003 in recognition of these contributions. Dr. Leffell also chaired the Southeastern Organ Procurement Foundation’s (now known as the American Foundation for Donation and
Transplantation) Histocompatibility Committee and has served as a faculty member and course advisor for that organization’s highly regarded Histocompatibility Specialist Course since its founding in 1982. She has contributed to the development of transplantation policies though her service in various capacities to the national Organ Procurement and Transplantation Network / United Network for Organ Sharing (OPTN/ UNOS), which have included two terms on the Board of Directors, serving as Chair of the Histocompatibility Committee, and as a member on the Kidney Transplant and Kidney Allocation Review committee. She has been a member of the Advisory Committee on Organ Transplantation to the Secretary of the Department of Health and Human Services and is currently a Councilor for the International Histocompatibility and Immunogenetics workshops.
ASHI Distinguished Service Award

This ASHI Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to serving ASHI.

The winner of the 2011 Distinguished Service Award is:

Danny Youngs, BS, CHS
Puget Sound Blood Center
(Award Supported by Linkage Biosciences, Inc.)

Daniel Young graduated from the University of Washington in 1979 with a bachelor of science degree in botany, and a few months later began his 31 year career in HLA as a technologist in the combined Puget Sound Blood Center/Fred Hutchinson Cancer Research Center Histocompatibility Laboratory in Seattle.

When the combined Puget Sound/Fred Hutch laboratory split up in 1989, Danny became supervisor of Puget Sound Blood Center’s Immunogenetics Laboratory, and has remained in that role to the present.

Danny has been an ASHI member since 1989, and was accredited as a Certified Histocompatibility Specialist in 1990. He has authored or coauthored two ASHI Quarterly articles, chapters in the Tenth International Histocompatibility Workshop book and the Clinical Transplants 2007 book, and more than three dozen abstracts about HLA. He has often been an abstract reviewer for the ASHI meetings.

Danny has served ASHI as a laboratory inspector from 1990 through 1995, as a member of the ASHI/CAP Proficiency Testing Committee from 1994 to 1997, and as a member of the ASHI Quality Assurance and Standards Committee from 2002 to 2004. Danny’s biggest contribution to ASHI has been the last 5 years working on the ASHI Proficiency Testing Committee – the first three years as Chair or Co-chair, and the last two years as Data Manager for the PT Program.
ASHI Outstanding Technologist Award

The Outstanding Technologist Award has honored some of the most active and creative technologists in the field of HLA. Candidates must have made significant and sustained contributions to ASHI. This year the Outstanding Technologist Award is dedicated to the memory of Joan E. Holcomb, MS, CHS.

The winner of the 2011 Outstanding Technologist Award is:

Dean Sylvaria, BS, CHS
Beth Israel Deaconess Medical Center
(Award Supported by the National Marrow Donor Program)

Dean Sylvaria, BS, CHS(ABHI) is the supervisor of the HLA Laboratory at Beth Israel Deaconess Medical Center, Boston, Massachusetts. Dean started his career in histocompatibility and immunogenetics in 1993 across the street at Brigham & Women’s Hospital. He has been a member of ASHI since 1994. His professional contributions include developing and promoting ASHI University, service to the Education Committee (multiple terms), Chair of the Education Committee with responsibility for planning the ASHI Regional Workshops (2008-present), service on the Audit and Finance Committee (2008-present), service as an ASHI inspector since 2000 and Commissioner for the Accreditation Review Board (2009-present), UNOS Histocompatibility Committee representative for Region 1 (2008-2010) and member of the Annual Program Planning Committee (2009-present). Dean has also held several positions on local committees, serving on BWH’s Laboratory Safety Committee (1995-2007), as well as the Quality Assurance Committee and Donor Selection Committee (2007-present) for the Transplant Institute at Beth Israel Deaconess Medical Center. Dean enjoys sharing his experience and knowledge of HLA with technologists, residents and clinicians while serving the transplant community.
ASHI has established the ASHI/SEOPF Award honoring J. Marilyn MacQueen. Marilyn was active in immunogenetics and histocompatibility testing since 1964, and was committed to helping young technologists in ASHI or SEOPF-accredited laboratories worldwide. The ASHI/SEOPF J. Marilyn MacQueen Award is presented annually to an outstanding HLA technologist who has worked in the field for less than 36 months and wants to pursue a career in HLA.

The winner of the 2011 J. Marilyn MacQueen Award is:

Christine Yamniuk, BS, BA
University of Alberta Hospital

Christine Yamniuk was born in 1984 in Montreal, Quebec, Canada and was raised in Edmonton, Alberta, Canada. She attended the University of Alberta and graduated with a Bachelor of Science (Medical Laboratory Sciences) in May 2006. After completing a research project under the direction of Dr. Patricia Campbell (MBChB, FRCPUK, FRCPC) as a part of her degree, Christine began working in the Edmonton Histocompatibility Laboratory on a temporary full-time basis in December, 2008 as a Lab Technologist I. She was keenly interested in the area and recognized the potential of the HLA lab to directly and positively impact the transplant recipient population. Christine immediately became involved in several initiatives within the lab, including implementing the Histotrac software system, which was integral in increasing the efficiency and accuracy of test reporting in the lab, validation and implementation of the Luminex cytometer for identification of HLA antibodies, and validation of the rSSO methodology for HLA typing.

After returning from a one-year maternity leave in January 2011, Christine accepted the position of Senior Technical Supervisor for the HLA lab. This represents an amazing learning opportunity for Christine as she embarks on several initiatives such as achieving ASHI accreditation for the laboratory, preparation for emerging national projects such as the Canadian National Organ Waitlist and the Highly Sensitized Patient Registry, and challenging the CHS exam.

Christine is mother to a beautiful 18-month old son and enjoys spending time with family, gardening and traveling in her free time. Christine would like to thank her family and friends for supporting her in her busy lifestyle. She would also like to thank Dr. Patricia Campbell, Anne Halpin (MSc CHS) and all of her co-workers for providing guidance, encouragement and support over the past few years.
ASHI Scholars and International Scholar Awards

The best abstracts submitted for the 2011 Annual Meeting will be recognized during the Awards Symposium and the submitters will give an oral presentation during the Special Abstract Scholar Session. These abstracts received the highest ratings by the reviewers, and the awards are provided to recognize individuals who made a significant advance in either clinical or basic research areas. The authors were selected from more than 296 submitted abstracts. Recipients receive a monetary award and certificate of recognition for their research.

Special Abstract Session: Scholar Awards
Thursday, October 20 2:30 pm – 4:00 pm

Amador Gonçalves-Primo, BSC • ASHI International Scholar
Federal University of San Paulo
Sao Paulo, Brazil

Abstract #40-OR: Low BCL2 mRNA Levels in Pre-Implantation Biopsies are Associated with Delayed Graft Function after Deceased Donor Kidney Transplantation. (Award Supported by ELSEVIER)

Abeer Madbouly, PhD • ASHI Scholar
National Marrow Donor Program
Minneapolis, MN

Abstract # 41-OR: Validation of Statistical Imputation of Allele-Level Multi-Locus Phased genotypes Through Structural Analysis of Ambiguous HLA. (Award Supported by STEMCELL Technologies, Inc.)

Xiaohai Zhang, PhD • ASHI Scholar
University of California, Los Angeles
Los Angeles, CA

Abstract #42-OR: HLA Class II Antibodies Elicit Intracellular Signal Transduction in Endothelial Cells. (Award Supported by Promega Corporation)
ASHI Scholars and International Scholar Awards

Nicole Leahy, PhD • ASHI Scholar
National Marrow Donor Program
Minneapolis, MN

Abstract #43-OR: Automated Pedigree Analysis Including Ambiguous and Incomplete Typing. (Award Supported by Qiagen, Inc.)
New Orleans
Schedule At a Glance

**Monday, October 17**

8:00 am – 5:00 pm  
**Accreditation Inspectors’ Training Workshop**  
Rhythms Ballroom, 2nd Floor

9:00 am – 3:30 pm  
**GenDX: HLA SBT Workshop (ABHI accredited)**  
Nottoway, 4th Floor

Noon – 7:00 pm  
**Registration Open**  
Grand Ballroom Foyer, 5th Floor

5:30 pm – 7:00 pm  
**Accreditation & Proficiency Testing Update**  
Grand Ballroom A/B/C, 5th Floor

7:00 pm – 8:00 pm  
**Keynote Address**  
Grand Ballroom A/B/C, 5th Floor

Introduction  
Geoffrey Land, PhD, HCLD

Defining Metrics of Immunological Health  
Mark M. Davis, PhD

8:00 pm – 9:00 pm  
**Welcome Reception**  
Grand Ballroom Foyer, 5th Floor

**Tuesday, October 18**

7:30 am – 6:00 pm  
**Registration Open**  
Grand Ballroom Foyer, 5th Floor

7:30 am – 8:15 am  
**Introduction to the Day**  
Grand Ballroom A/B/C, 5th Floor

Adriana Zeevi, PhD, D(ABHI)  
Anat Tambur, DMD, PhD, D(ABHI)
Schedule At a Glance

**Tuesday, October 18**

8:30 am – 10:00 am  
**Plenary I: Transplantation**  
Grand Ballroom A/B/C, 5th Floor

**Moderators**  
Phillip Ruiz, MD, PhD  
Anat Tambur, DMD, PhD, D(ABHI)

**T Cell Immunology (T-cell Tolerance in Solid Organ Transplantation)**  
Minnie Sarwal, MD, MRCP, DCH, PhD

**The Role of B Cells in T Cell Autoimmunity and Graft Rejection**  
Geetha Chalasani, MD

10:00 am – 10:30 am  
**AM Refreshment Break**  
Napoleon Ballroom, 3rd Floor

10:00 am – 12:15 pm  
**Exhibits/Posters Open**  
Napoleon Ballroom, 3rd Floor

10:30 am – 12:15 pm  
**Symposium I: New Therapies**  
Grand Ballroom A/B/C, 5th Floor

**Moderators**  
Dolly Tyan, PhD, D(ABHI)  
Adriana Zeevi, PhD, D(ABHI)

**Liver Transplantation**  
Sandy Feng, MD, PhD

**Pathology with Response to Treatment**  
Milagros Samaniego-Picota, MD

**Hand Transplantation**  
Gerald Brandacher, MD

12:15 pm – 2:30 pm  
**Human Immunology Editorial Board Luncheon**  
Nottoway, 4th Floor
Schedule At a Glance

Tuesday, October 18

12:15 pm – 2:30 pm

**User Group Luncheons**
Absorber AB/Olerup, Inc.:
XM-ONE, Clinical Update
Oak Alley, 4th Floor

Life Technologies Sequencing-Based Typing (SBT) HLA Workflow Solution: Registry and Laboratory Customer Perspectives
Waterbury Ballroom, 2nd Floor

One Lambda: One Lambda Technical Luncheon
Rhythms Ballroom, 2nd Floor

STEMCELL Technologies, Inc.:
Fast and Easy Isolation of Specific Cell Populations for Chimerism Analysis
Grand Couteau, 5th Floor

SystemLink Inc.: HistoTrac User’s Group Meeting
Bayside A/B/C, 4th Floor

2:30 pm – 4:00 pm

**Workshop 1: Case Studies in Stem Cell Transplantation**
Grand Ballroom A/B, 5th Floor

**Moderator**
Myra Coppage, PhD, HCLD, (ABB)

**Workshop 2: Population Genetics**
Grand Ballroom C, 5th Floor

**Moderator**
Martin Maiers

Steven Mack, PhD
Jill Hollenbach, PhD
**Schedule At a Glance**

**Tuesday, October 18**

2:30 pm – 4:00 pm  
**Abstract Session 1: Solid Organ: Pre-Transplant Testing**  
Grand Ballroom E, 5th Floor  

**Moderator**  
Nancy L. Reinsmoen, PhD, D(ABHI)

2:30 pm – 7:00 pm  
**Exhibits/Posters Open**  
Napoleon Ballroom, 3rd Floor

4:00 pm – 4:30 pm  
**PM Refreshment Break**  
Napoleon Ballroom, 3rd Floor

4:30 pm – 6:00 pm  
**Workshop 3: MFI’s: The Continuing Story**  
Grand Ballroom A/B, 5th Floor  

**Moderator**  
Patrick Adams, MS, CHS, (ABHI)  
Nicholas DiPaola, PhD  
Donna Phelan, BA, MT(HEW), CHS

6:00 pm – 7:30 pm  
**International Histocompatibility Workshop Update**  
Grand Ballroom E, 5th Floor  

**Moderator**  
Steven G.E. Marsh, PhD  
Derek Middleton, DSc, PhD, FRC

6:00 pm – 7:30 pm  
**Poster Session & Reception**  
Napoleon Ballroom, 3rd Floor
## Schedule At a Glance

**Wednesday, October 19**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 pm – 9:30 pm</td>
<td><strong>ASHI/ARB Inspectors’ &amp; International Reception</strong></td>
<td>Gallery, 1st Floor</td>
</tr>
<tr>
<td>7:30 am – 6:00 pm</td>
<td><strong>Registration Open</strong></td>
<td>Grand Ballroom Foyer, 5th Floor</td>
</tr>
<tr>
<td>7:30 am – 8:15 am</td>
<td><strong>Introduction to the Day</strong></td>
<td>Grand Ballroom A/B/C, 5th Floor</td>
</tr>
<tr>
<td>Steven Mack, PhD</td>
<td><strong>Plenary II: HLA Immune Response &amp; Disease</strong></td>
<td>Grand Ballroom A/B/C, 5th Floor</td>
</tr>
<tr>
<td>William Hildebrand, PhD, D(ABHI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 am – 10:00 am</td>
<td><strong>Moderators</strong></td>
<td></td>
</tr>
<tr>
<td>Derek Middleton, DSc, PhD, FRC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven Mack, PhD</td>
<td><strong>HLA &amp; Disease Associations</strong></td>
<td></td>
</tr>
<tr>
<td>Henry Erlich, PhD</td>
<td><strong>Immunogenetic Factors that Determine the Course of Infectious Diseases</strong></td>
<td>Mary Carrington, PhD, MS</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td><strong>AM Refreshment Break</strong></td>
<td>Napoleon Ballroom, 3rd Floor</td>
</tr>
<tr>
<td>10:00 am – 12:15 pm</td>
<td><strong>Exhibits/Posters Open</strong></td>
<td>Napoleon Ballroom, 3rd Floor</td>
</tr>
<tr>
<td>10:30 am – 12:15 pm</td>
<td><strong>Symposium II: Tissues Response to Antibody Injury</strong></td>
<td>Grand Ballroom A/B/C, 5th Floor</td>
</tr>
<tr>
<td>Robert Bray, PhD, D(ABHI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>William Hildebrand, PhD, D(ABHI)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Schedule At a Glance

**Wednesday, October 19**

**Innate and Adaptive Immunity in Lung Transplant**
John Belperio, MD

**Functional Autoantibodies Against Vascular Receptors**
Duska Dragun, MD

**Biological Function and Clinical Relevance of Antibodies to HLA Antigens**
Elaine Reed, PhD, D(ABHI)

12:15 pm – 2:30 pm

**User Group Luncheons**

**Abbott Molecular: New Technology Opportunities in Solid Organ Transplant Testing**
Supported by Abbot Molecular
Rhythms Ballroom, 2nd Floor

**Linkage Biosciences:**
**Luncheon Symposium**
Bayside A/B/C, 4th Floor

**Olerup SSP AB/Olerup, Inc.:**
**SSP or SBT vs SSP + SBT**
Nottoway, 4th Floor

**Roche 454-Sequencing: Next-Gen Sequencing for High Resolution HLA Typing Luncheon**
Gallery, 1st Floor

2:30 pm – 4:00 pm

**Workshop 4: Case Studies in Solid Organ Transplantation**
Grand Ballroom C, 5th Floor

**Moderator**
Annette Jackson, PhD
Schedule At a Glance

**Wednesday, October 19**

**Workshop 5: Non-HLA/Non-MHC Antibodies & Allograft Destruction**
Grand Ballroom A/B, 5th Floor

Smita Vaidya, PhD  
Dawn Wagenknecht, MS, CHS  
John McIntyre, PhD, D(ABHI)

**Abstract Session 3: HLA Genetics and Polymorphism**
Grand Ballroom E, 5th Floor

**Moderators**
Shalini E. Pereira, PhD, D(ABHI)

**Abstract Session 4: Cell Signalling and Activation**
Grand Ballroom D, 5th Floor

**Moderator**
Elaine F. Reed, PhD, D(ABHI)

2:30 pm – 6:00 pm  
**Exhibits/Posters Open**  
Napoleon Ballroom, 3rd Floor

4:00 pm – 4:30 pm  
**PM Refreshment Break**  
Napoleon Ballroom, 3rd Floor

4:30 pm – 6:00 pm  
**Annual Business Meeting**  
Grand Ballroom C, 5th Floor

6:00 pm – 7:30 pm  
**Directors’ Forum**  
Grand Ballroom C, 5th Floor

**Technologists’ Forum**  
Grand Ballroom A/B, 5th Floor

10:00 pm  
**One Lambda’s Annual ASHI Bash at Generation Hall**
**Schedule At a Glance**

**Thursday, October 20**

7:00 am – 8:00 am  
**Vendor Meeting**  
Oak Alley, 4th Floor

7:30 am – 6:00 pm  
**Registration Open**  
Grand Ballroom Foyer, 5th Floor

7:15 am – 8:15 am  
**CPT Workshop**  
Grand Ballroom A/B/C, 5th Floor

**Moderators**
- Maria Bettinotti, PhD, D(ABHI)
- Tom Williams, MD, D(ABHI)
- Sandra Helman, PhD, D(ABHI)

8:30 am – 10:00 am  
**Plenary III: Emerging Technologies**  
Grand Ballroom A/B/C, 5th Floor

**Moderators**
- Daniel Cook, PhD, D(ABHI)
- Malek Kamoun, MD, PhD

- Quantum Dot, Immunostaining & High Resolution Imaging  
  A.J. Demetris, MD

- The Structure of the Immune Network & Decadent Descendence in Cancer Suborned Lineages by Mass Cytometry  
  Sean Bendall, PhD

10:00 am – 10:30 am  
**AM Refreshment Break**  
Napoleon Ballroom, 3rd Floor

10:00 am – 12:30 pm  
**Exhibits/Posters Open**  
Napoleon Ballroom, 3rd Floor

10:30 am – 12:30 pm  
**Symposium III: Awards**  
Grand Ballroom A/B/C, 5th Floor
**Schedule At a Glance**

**Thursday, October 20**

**2:30 pm – 4:00 pm**

**Workshop 6: Harmonization of HLA Terminology and Reporting**
Grand Ballroom C, 5th Floor

Carolyn Hurley, PhD, D(ABHI)
Cyndi Taves, PhD, D(ABHI)
Dawn Wagenknecht, MS, CHS

**Special Abstract Session: Scholar Awards**
Grand Ballroom A/B, 5th Floor

**Moderators**
Paul I. Terasaki, PhD
Martin Maiers
Elaine Reed, PhD, D(ABHI)

**Abstract #40-OR:** Low BCL2 mRNA Levels in Pre-Implantation Biopsies are Associated with Delayed Graft Function after Deceased Donor Kidney Transplantation.
Maria Gerbase-DeLima, MD, PhD

**Abstract #41-OR:** Validation of Statistical Imputation of Allele-Level Multi-Locus Phased genotypes Through Structural Analysis of Ambiguous HLA.
Abeer Madbouly, PhD

**Abstract #42-OR:** HLA Class II Antibodies Elicit Intracellular Signal Transduction in Endothelial Cells.
Xiaohai Zhang, PhD

**Abstract #43-OR:** Automated Pedigree Analysis Including Ambiguous and Incomplete Typing.
Nicole Leahy, PhD
## Schedule At a Glance

### Thursday, October 20

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 4:00 pm – 4:30 pm | PM Refreshment Break
                        Grand Ballroom Foyer, 5th Floor                                                                 |
| 4:30 pm – 6:00 pm | **Workshop 7: Finding the Right Donors for Stem Cell Transplant Patients**
                        Grand Ballroom A/B, 5th Floor
                        Susana Marino, MD, PhD, D(ABHI)
                        Marcos de Lima, MD                                                                                       |
|                 | **Abstract Session 5: Solid Organ: Post-Transplant Testing**
                        Grand Ballroom C, 5th Floor
                        **Moderator**
                        Nicole Suciu-Foca, PhD, MS, BS                                                                                 |
| 7:00 pm – 1:00 am | **Annual Banquet**
                        House of Blues Featuring Soul Incision
                        Ticketed event
                        225 Decatur Street                                                                                          |

### Friday, October 21

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 7:30 am – 10:00 am | **Registration Open**
                        Grand Ballroom Foyer, 5th Floor                                                                              |
| 7:30 am – 8:15 am | **Introduction to the Day**
                        Grand Ballroom A/B/C, 5th Floor
                        Lee Ann Baxter-Lowe, PhD, D(ABHI)
                        Sandra Rosen-Bronson, PhD, D(ABHI)                                                                          |
Schedule At a Glance

**Friday, October 21**

8:30 am – 10:45 am  
**Update on Bone Marrow**  
Grand Ballroom A/B/C, 5th Floor

**Moderators**  
Carlheinz Mueller, MD, PhD, ZKRD  
Sandra Rosen-Bronson, PhD, D(ABHI)

**Factors (including HLA mismatches) Considered for Selection of Type of Graft, Therapy, Etc.**  
Marcos de Lima, MD

**Immune Reconstitution After Allogeneic HSC**  
Nelson Chao, MD

**Genetic Factors Detected by Genomes Wide Scans that Determine Outcomes in Allogeneic HSC**  
John Hansen, MD

10:45 am – 11:15 am  
**AM Refreshment Break**  
Grand Ballroom Foyer, 5th Floor

11:15 am – 12:30 pm  
**Update on Solid Organ**  
Grand Ballroom A/B/C, 5th Floor

**Moderators**  
Lee Ann Baxter-Lowe, PhD, D(ABHI)  
Geoffrey Land, PhD, HCLD

**The Development of CPRA: What Has Been Achieved So Far**  
Mary Sue Leffell, PhD, ABMLI, D(ABHI)

**The Impact of CPRA on Transplant Rates: Current and Future Directions**  
Nancy Reinsmoen, PhD, D(ABHI)
Abstracts

Tuesday, October 18, 2011
2:30 PM - 4:00 PM
Workshop 1: Case Studies in Stem Cell Transplantation

1-OR
IDENTIFICATION OF A NOVEL DRB1*08:01 HAPLOTYPE CARRYING
DRB3*01:01 BY MOLECULAR METHODS.
Kai Cao, Qi Wang, Mehrnoush Naim, Chih-Hung Lai, Geraldine Ong, Nancy L. Reinsmoen.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

2-OR
SEARCHING FOR DRB1*08:11.
Anajane Smith, Judy Davis. Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

3-OR
A CHALLENGE IN HLA TYPING IN PATIENTS WITH REFRACTORY APLASTIC
ANEMIA AND HAPLOTYPE SPECIFIC PREFERENTIAL AMPLIFICATION.
Gansuvd Balgansuren, Angelica DeOliveira, Bobbie Holeman, Candace Young, Adella Clark,
Dong-Feng Chen. Clinical Transplantation Immunology Laboratory, Duke University Medical Cen-
ter, Durham, NC, USA.

4-OR
HAPLOTYPE LOSS.
Paula Y. Arnold, Sheila Shurtleff, Victoria Turner. Pathology, HLA Laboratory and Molecular Patho-
logy Laboratory, St. Jude Children’s Research Hospital, Memphis, TN, USA.

5-OR
T CELL SELECTION AND CD3 EXPRESSION IN LINEAGE SPECIFIC CHIME-
RISM ANALYSIS.
Yenhui Chang, Cherry Jo Pascual, Perla Alonzo, Adam Coovadia, Tom Mueller, Wilfredo Chami-
zo. Pathology and Laboratory Medicine, All Children’s Hospital, St. Petersburg, FL, USA.

6-OR
A CASE OF REJECTION IN 10/10 ALLELE MATCHED TRANSPLANT WITH
“HIGH TITER LOW AVIDITY” HLA-DP DONOR SPECIFIC ANTIBODIES.
Manish J. Gandhi, Steven R. DeGoey, Cynthia M. Kroning, Brittany Schneider, James Stubbs,
William Hogan, Mark Litzow, Dennis Gastineau. Division of Transfusion Medicine and Hematolo-
gy, Mayo Clinic, Rochester, MN, USA.
Abstracts

Tuesday, October 18, 2011
2:30 PM - 4:00 PM
Abstract Session 1: Solid Organ: Pre-Transplant Testing

7-OR
ROLE OF ANTI-HLA ANTIBODY ASSESSMENT AND RISK STRATIFICATION IN HEART TRANSPLANTATION.
Kai Cao, Chih-Hung Lai, Geraldine Ong, Mehrnoush Naim, Qi Wang, Jon Kobashigawa, Nancy L. Reinsmoen. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

8-OR
A NOVEL ELISPOT ASSAY TO QUANTIFY HLA-SPECIFIC B CELLS IN HLA-IMMUNIZED INDIVIDUALS.
Sebastiaan Heidt1, Dave L. Roelen1, Yvonne J.H. de Vaal1, Chantal Eijsink1, Sybill Thomas2, Hans-Dieter Volk2, Michel G.D. Kester4, Frans H.J. Claas1, Arend Mulder1. 1Dept. of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 2Institute of Medical Immunology, Campus Charité Mitte, Charite University Medicine, Berlin, Germany; 3Dept. of Haematology, LUMC, Leiden, Netherlands.

9-OR
ASSOCIATION OF HIGH SOLUBLE CD30 SERUM LEVELS WITH KIDNEY SUBCLINICAL ACUTE REJECTION.
Erika F. Campos1,2, Patricia Grenzi1, Helio Tedesco-Silva3, Claudia R. Felipe2,3, Marcello Franco2, José O. Medina-Pestana2,3, Maria Gerbase-Delima1,2. 1Immunogenetics, Associação Fundo de Incentivo à Pesquisa, São Paulo, SP, Brazil; 2Universidade Federal de Sao Paulo, São Paulo, SP, Brazil; 3Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, São Paulo, SP, Brazil; 4Brazil.

10-OR
A MORE ACCURATE ASSESSMENT OF EFFICACY OF ANTIBODY REDUCTION BY PLASMAPHERESIS OR BORTEZOMIB IS REVEALED BY TESTING SERA IN DILUTIONS.
Mikki Ozawa1, Paul I. Terasaki1, Nubia Banuelos1, Josephina Alberu2, Luis E Morales-Buentostro2. 1Research II, One Lambda, Inc., Los Angeles, CA, USA; 2Nephrology, National Institute of Medical Science and Nutrition, Mexico City, Mexico.

11-OR
VIRTUAL CROSMatch BASED ON CLASS I HLA EPITOPE (EPLLET) ANALYSIS (HLAMatchmaker) FOR SERA OF HIGHLY SENSITIZED PATIENTS INCREASES THE NUMBER OF COMPATIBLE DONORS IN KIDNEY PAIRED DONATION PROGRAM.
Beata Mierzejewska1, Paul Schroder2, Kelly Miller1, Audrey Roberts1, Annette Blair2, Connie Smith2, Rene Duquesnoy3, Michael Rees1, Stanislaw Stepkowski2. 1Department of Urology, University of Toledo, Toledo, OH, USA; 2Department of Microbiology&Immunology, University of Toledo, Toledo, OH, USA; 3Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Abstracts

12-OR
KIDNEY PAIRED DONATION (KPD) IN A SINGLE CENTER – A PARADIGM SHIFT.
Anat R. Tambur, Nicole Beauvais,, Emily Warren, Maria Hendricks, Joe Leventhal, John Frie-
dewald. Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA.

Tuesday, October 18, 2011
2:30 PM - 4:00 PM
Abstract Session 2: New Assays and Emerging Technologies

13-OR
COMPUTATIONAL MODELING OF PEPTIDES INTO HLA-A*02:01 MOLECULES.
T. Andrew Binkowski1, Susana R. Marino2, Andrzej Joachimiak1. 1Center for Structural Genomics of Infectious Diseases & Midwest Center for Structural Genomics Biosciences Division, Argonne National Laboratory, Argonne, IL, USA; 2Pathology, University of Chicago Medical Center, Chicago, IL, USA.

14-OR
PARALLEL C1q AND IgG ASSAYS ON SINGLE ANTIGEN BEADS REVEAL THAT THE PRESENCE OF IgM COMPLEMENT FIXING ANTIBODIES CAN OBSCURE CLINICALLY RELEVANT IgG ANTIBODIES TO THE SAME ALLELE.
Ge Chen, Flavia Sequeira, Dolly Tyan. Pathology, Stanford University, Palo Alto, CA, USA.

15-OR
PROFILING OF SELF PEPTIDES DERIVED FROM LYMPHOBLASTIC CELLS SELECTED BY B*44 VARIANTS.
Christina Bade-Doeding, Trevor Huyton, Britta Eiz-Vesper, Rainer Blasczyk. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

16-OR
ASSOCIATION OF C4d STAINING, SINGLE ANTIGEN ANTIBODY ANALYSIS AND THE C1q BINDING ASSAY.
Debra Kukuruga1, Cinthia Drachenberg3, Abdolreza Haririan2. 1Pathology, University of Maryland Medical Center, Baltimore, MD, USA; 2Nephrology, University of Maryland School of Medicine, Baltimore, MD, USA; 3Pathology, University of Maryland School of Medicine, Baltimore, MD, USA; 4One Lambda, Inc., Canoga Park, CA, USA.

17-OR
LUMINEX-C1q: A RELIABLE VIRTUAL CROSSMATCH (VXM) TO PREDICT FINAL CDC CROSSMATCH.
Ge Chen, Flavia Sequeira, Dolly Tyan. Pathology, Stanford University, Palo Alto, CA, USA.
Abstracts

18-OR
CHARACTERIZATION OF HLA-A *0101 AND HLA-B* 0702 EPITOPES IN HIV-1 Nef USING THE iTopia EPITOPE DISCOVERY SYSTEM.
Tomasz M. Bielawny1, Francis A. Plummer1,2, Ma Luo1,2, 1HIV and Human Genetics, National Microbiology Laboratory of Canada, Public Health Agency of Canada, Winnipeg, MB, Canada; 2Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.

19-OR
NEW DIRECTIONS IN HLA AND DISEASE ASSOCIATIONS: THE SEARCH BEYOND HLAs USING GENOME-WIDE SNP-GENOTYPING AND NEXT GENERATION SEQUENCING.
Dimitri Monos1, Tasha Fingerlin3, Katarzyna Mackiewicz1, Anna Papazoglou1, Milton Rossman2, Kenneth Rosenman4, Jonathan Bradfield2, Peggy Mroz2, Lori Silvera3, Hakon Hakonarson2, Lisa Maier3. 1Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine and The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 2Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 3Department of Medicine, University of Colorado and the National Jewish Health, Denver, CO, USA; 4Department of Medicine, Michigan State University, East Lansing, MI, USA; 5Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA.

Wednesday, October 19, 2011
2:30 PM - 4:00 PM
Workshop 4: Case Studies in Solid Organ Transplantation

20-OR
MULTIPLE ACCELERATED REJECTIONS IN THE ABSENCE OF COMPLEMENT ACTIVATION IN A PATIENT WITH ENDOTHELIAL CELL REACTIVE ANTIBODY.
Annette M. Jackson1, Michael Kuperman2, Robert A. Montgomery3. 1Medicine, Johns Hopkins University, Baltimore, MD, USA; 2Pathology, Johns Hopkins University, Baltimore, MD, USA; 3Surgery, Johns Hopkins University, Baltimore, MD, USA.

21-OR
SERUM DILUTION IN THE LUMINEX SINGLE ANTIGEN ASSAY MAY REVEAL PREVIOUSLY UNDETECTED STRONG DSA IN SENSITIZED PATIENTS.
Jason Payne1, Tammi Whitted1, Kathie Nelson1, Brian Gallay2, Patricia Kopko1. 1HLA, BloodSource, Mather, CA, USA; 2Transplant Nephrology Section, UC Davis Medical Center, Sacramento, CA, USA.

22-OR
WHY DID TWO PATIENTS WHO TYPE FOR HLA-B13 HAVE ANTIBODIES THAT REACT WITH ALL Bw4 ANTIGENS EXCEPT HLA-B13?
Marilyn Marrari1, Raffaella Conca2, Rene J. Duquesnoy1. 1Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 2San Giovanni Hospital, University of Torino, Torino, Italy.
Abstracts

23-OR
SUCCESSFUL RENAL TRANSPLANTATION ACROSS THREE DONOR SPECIFIC ANTIBODIES.
Cheryl L. Thompson1, Donna Phelan1, James Cicciarelli2, T. Mohanakumar3. 1HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; 2Immunogenetics Lab, MNIT, Los Angeles, CA, USA; 3Department of Surgery, Washington University, St. Louis, MO, USA.

24-OR
TO PROCEED OR NOT PROCEED? A SINGLE EPITOME REACTIVITY WITH MULTIPLE STRONG Cw SPECIFICITIES YIELDING A NEGATIVE CROSSMATCH.
Christine Yamniuk, Patricia Campbell, Anne Halpin, Luis Hidalgo. Histocompatibility, University of Alberta Hospital, Edmonton, AB, Canada.

25-OR
DESENSITIZATION AND LIVING DONOR KIDNEY TRANSPLANT USING A NOVEL INDUCTION REGIMEN WITHOUT REJECTION.
Daniel Borja-Cacho1, Gerardo Tamayo1, Harriet Noreen2, Peggy Krefting2, David Maurer2, Ty B. Dunn1. 1Surgery, University of Minnesota Medical Center, Minneapolis, MN, USA; 2Lab Medicine & Pathology, University of Minnesota Medical Center, Minneapolis, MN, USA.

Wednesday, October 19, 2011
2:30 PM - 4:00 PM
Abstract Session 3: HLA Genetics and Polymorphism

26-OR
THE STRUCTURAL CONSTRAINT OF THE PEPTIDE MOTIF FOR B*44:06 CAN BE ATTRIBUTED TO RESIDUE 63 IN THE HEAVY CHAIN.
Christina Bade-Doeding, Trevor Huyton, Heike Schumacher, Rainer Blasczyk. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

27-OR
MISMATCHES OUTSIDE EXON 2 AND 3 DO NOT ALTER THE FUNCTION OF THE ALLELE GROUP B*44:02P.
Christina Bade-Doeding1, Pedro Cano2, Trevor Huyton1, Britta Eiz-Vesper1, Oliver Hiller1, Soumya Badrinath1, Rainer Blasczyk1. 1Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany; 2M. D. Anderson Cancer Center, The University of Texas, Houston, USA.
Abstracts

28-OR
CONTROL OF HIV-1 REPLICATION: HUMAN LONG-TERM NON-PROGRESSORS AND CHIMPANZEE SHARE MHC CLASS I MOLECULES WITH SIMILAR FUNCTIONAL PROPERTIES.
Natasja G. de Groot1, Corrine M.C. Heijmans1, Yvonne M. Zoet2, Arnoud H. de Ru2, Frank A. Verreck1, Peter A. van Veelen2, Jan W. Drijfhout3, Gaby G.M. Doxiadis1, Edmond J. Remarque1, Ilias I.N. Doxiadis2, Frits Koning2, Ronald E. Bontrop1. 1Comparative Genetics and Refinement and Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands; 2Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.

29-OR
EXTENDED HLA HAPLOTYPES CONTAINING B*41:02–C*17:03.
Joshua J. Loomis1, Lois E. Regen1, Chin H. Boo2, Rita C. Witherspoon1, Randolph Williams1, Shalini E. Pereira1,2,3. 1Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

30-OR
INFLUENCE OF HLA CLASS I AND KIR GENOTYPES ON HIV-1 POSITIVE SUBJECTS FROM RIO GRANDE DO SUL, BRAZIL.
Juliana Cardoso Oliveira1, Gustavo Milson Fabricio-Silva1, Magda Cristina Bernardino Castilho1, Monica Barcellos Arruda2, Theodoro Armando Siffert3, Luis Cristovao Porto1, Luis Fernando Job Jobim4, Mariana Jobim4, Patricia Salim4, Amilcar Tanuri2, Orlando Costa Ferreira, Jr1. 1HLA and Cryopreservation Laboratory, State University of Rio de Janeiro, Rio de Janeiro, Brazil; 2Molecular Virology Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; 3Department of Immunology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

31-OR
KIR GENOTYPES INDICATIVE OF LESS INHIBITION BUT MORE ACTIVATION ARE STRONGLY ASSOCIATED WITH PULMONARY TUBERCULOSIS (PTB).
Raja Rajalingam1, Surendra K. Sharma2. 1UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA, USA; 2Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.

32-OR
CLUSTERING HLA ALLELES BY SEQUENCE FEATURE VARIANT TYPE (SFVT).
Loren Gragert, Michael Halagan, Martin Maiers. Bioinformatics Research, National Marrow Donor Program, Minneapolis, USA.
Abstracts

Wednesday, October 19, 2011
2:30 PM - 4:00 PM
Abstract Session 4: Cell Signalling and Activation

33-OR
MONOCYTE ADHERENCE TO HLA CLASS I ANTIBODY-ACTIVATED ENDOTHELIAL CELLS EXPRESSING P-SELECTIN IS AMPLIFIED BY FcγR ENGAGEMENT.
Nicole M. Valenzuela1, Elaine F. Reed1,2. 1Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA; 2Immunogenetics Center, University of California, Los Angeles, CA, USA.

34-OR
NOT ALL CLASS I MOLECULES ASSOCIATE WITH INTEGRIN beta4 TO TRANSDUCE SIGNALS: MECHANISMS AND CLINICAL IMPLICATIONS.
Yi-Ping Jin1, Xiaohai Zhang1, Arend Mulder2, Frans H.J. Claas2, Jar-How Lee3, Elaine F. Reed1. 1Pathology & Lab Med, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA; 2Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 3One Lambda, Inc., Canoga Park, CA, USA.

35-OR
NK CELL ACTIVATION IS DEPENDENT ON HLA-E SURFACE EXPRESSION AND THE PEPTIDE PRESENTED BY HLA-E.
Nina Lauterbach, Lotte Wieten, Laura van Zon, Christina E.M. Voorter, Marcel G.J. Tilanus. Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Centre, Maastricht, Netherlands.

36-OR
THE CAPACITY OF POST-TRANSPLANT HLA ANTIBODY TO TRIGGER CELL SURVIVAL AND PROLIFERATION SIGNALS IN ENDOTHELIAL CELLS IS DEPENDENT UPON THE ANTIBODY TITER.
Fang Li, David W. Gjertson, Elaine F. Reed. Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, USA.

37-OR
MHC-E PRESENTS EXTENDED PEPTIDE LIGANDS.
Curtis P. McMurtrey1, Christina Bade-Döding2, Wilfried Bardet1, Ken Jackson1, Stephen Vernon1, Richard Rudersdorf3, David Watkins4, Rainer Blasczyk2, William Hildebrand1. 1Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 2Hannover Medical School, Institute for Transfusion Medicine, Hannover, Germany; 3Pathology and Laboratory Medicine, University of Wisconsin Madison, Madison, WI, USA; 4Oklahoma City.
Abstracts

38-OR
DOWNREGULATION OF MicroRNAs IN ILT3Fc INDUCED T SUPPRESSOR CELLS.
Chih-Chao Chang, Zhuoru Liu, Raffaello Cortesini, NicoleSuciu-Foca, George Vlad. Pathology and Cell Biology, Columbia University, New York, NY, USA.

39-OR
DENDRITIC CELLS DIFFERENTIATION AND CD1α EXPRESSION ARE REGULATED BY CD99 THROUGH ATF/CREB PHOSPHORYLATION PATHWAY.
Mouna Sghaier1,2, Hanene Bziouech1,3, Karim Mahiddine1, Aude Malavielle1, Alain Bernard1,2,3, Ghislaine Bernard1,2,3, 1Hôpital de L’Archet, INSERM U 576, Nice, France; 2Laboratoire d'Immunologie, Université de Nice, Nice, France; 3Immunologie, CHU de Nice, Nice, France.

Thursday, October 20, 2011
2:30 PM – 4:00 PM
Special Abstract Session: Scholar Awards

40-OR
LOW BCL2 mRNA LEVELS IN PRE-IMPLANTATION BIOPSIES ARE ASSOCIATED WITH DELAYED GRAFT FUNCTION AFTER DECEASED DONOR KIDNEY TRANSPLANTATION.
Amador Gonçalves-Primo1, Tuíla B. Mourão1,2, Vinicius Andrade-Oliveira1,2, Erika F. Campos1,2, Jose O. Medina-Pestana2,3, Helio Tedesco-Silva3, Maria Gerbase-Del Lima1,2, 1Immunogenetics, Associação Fundo de Incentivo à Pesquisa - AFIP, Sao Paulo, SP, Brazil; 2Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil; 3Hospital do Rim e Hipertensao - Fundação Oswaldo Ramos, Sao Paulo, SP, Brazil.

41-OR
VALIDATION OF STATISTICAL IMPUTATION OF ALLELE-LEVEL MULTI-LOCUS PHASED GENOTYPES THROUGH STRUCTURAL ANALYSIS OF AMBIGUOUS HLA.
Abeer S. Madbouly, Loren Gragert, John Freeman, Martin Maiers. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

42-OR
HLA CLASS II ANTIBODIES ELICIT INTRACELLULAR SIGNAL TRANSDUCTION IN ENDOTHELIAL CELLS.
Xiaohai Zhang, Elaine F. Reed. the UCLA Immunogenetics Center, University of California, Los Angeles, CA, USA.
Abstracts

43-OR
AUTOMATED PEDIGREE ANALYSIS INCLUDING AMBIGUOUS AND INCOMPLETE TYPING.
Nicole Leahy1, Abeer Madbouly1, Loren Gragert1, Craig Malmberg2, Jennifer Paulson2, Martin Maiers1. 1Bioinformatics, National Marrow Donor Program, Minneapolis, MN, USA; 2Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

Thursday, October 20, 2011
4:30 PM - 6:00 PM
Abstract Session 5: Solid Organ: Post-Transplant Testing

44-OR
DONOR-SPECIFIC MICA ANTIBODIES CORRELATE WITH CELLULAR REJECTION AND CHRONIC GRAFT DYSFUNCTION IN RENAL TRANSPLANT RECIPIENTS.
Steve Cox1, Ray Fernando2,3, Aliyye Karasu2,3, Henry Stephens2,3. 1Research Institute, The Anthony Nolan, London, United Kingdom; 2HLA Laboratories, The Anthony Nolan, London, United Kingdom; 3Royal Free Hospital, UCL Centre for Nephrology, London, United Kingdom.

45-OR
RENAL TRANSPLANT PATIENTS WITH LATE ANTIBODY MEDIATED REJECTION EXHIBIT MORE IgG3 AND/OR MULTIPLE IgG SUBTYPE COMBINATIONS WHEN COMPARED TO EARLY ANTIBODY MEDIATED REJECTION.

46-OR
15-YEAR ACTUARIAL SURVIVAL OF HEART ALLOGRAFTS IN PATIENTS MONITORED FOR ANTI-HLA ANTIBODIES BEFORE AND AFTER TRANSPLANTATION.
Elena R. Vasilescu1, George Vlad1, Eric Ho1, Charles Marboe1, Raphael Clynes1, Donna Mancini1, Nicole Suciu-Foca1. 1Pathology and Cell Biology, Columbia University, New York, NY, USA; 2Medicine, Columbia University, New York, NY, USA.

47-OR
HLA DQ ANTIBODIES ARE THE MOST FREQUENT ANTIBODIES ENCOUNTERED IN ANTIBODY-MEDIATED REJECTION (AMR) OF RENAL ALLOGRAFTS.
Khalid Al Meshari1, Abeed Pall1, Hazem Elgamal1, Fadi Alzayer2, Moheeb Al Awwami2. 1Renal Transplant, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2Pathology & Laboratory Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Abstracts

48-OR
A 13 YEAR STUDY TO INVESTIGATE PRODUCTION OF DE NOVO DSA ON GRAFT SURVIVAL AFTER HEART TRANSPLANTATION.
Anh Nguyen1, John D. Smith2, Matthew J. Everly1, Nicholas R. Banner3, Iman M. Hamour3, Marlene L. Rose2, Paul I. Terasaki4. 1Research II, One Lambda, Inc., Los Angeles, CA, USA; 2Transplant Immunology, Harefield Hospital, Imperial College, Harefield, United Kingdom; 3Transplant Cardiology, Harefield Hospital, Imperial College, Harefield, United Kingdom; 4Terasaki Foundation Laboratory, Terasaki Foundation Laboratory, Los Angeles, USA.

49-OR
IgG SUBCLASS DONOR SPECIFIC ANTIBODIES (DSA) IN TRANSPLANT PATIENTS: SUMMARY AND MONITORING FOR THE LAST TWO YEARS.
J. Cicciarelli1,2, N. Kasahara1, R. Adamson2, N. Lemp1, S. Steinberg2. 1Immunogenetics Lab, MINIT, Los Angeles, CA, USA; 2Heart and Renal Transplantation, Sharp Memorial Medical Center, San Diego, CA, USA.

50-OR
DEFINING INCIDENCE OF AND RISK FROM DSA BASED ON A PROSPECTIVE 10 YEAR LONGITUDINAL STUDY OF CONSECUTIVE RENAL TRANSPLANT RECIPIENTS.
Lorita M. Rebellato-deVente1, Matthew J. Everly2, Mikki Ozawa2, Kimberly P. Briley1, Paul G. Catrou1, Carl E. Haisch1, Paul I. Terasaki3. 1Brody School of Medicine, East Carolina University, Greenville, NC, USA; 2Research II, One Lambda Inc, Los Angeles, CA, USA; 3Terasaki Foundation, Los Angeles, CA, USA.

Thursday, October
4:30 PM - 6:00 PM
Abstract Session 6: Tolerance and Immune Regulation

51-OR
THE NOVEL MECHANISMS OF TOLERANCE INDUCTION CONTRIBUTE TO LONG TERM SURVIVAL OF HEART GRAFTS IN MHC CLASS I-MISMATCHED HOST.
Yuantao Wang1, Honglan Zhou1, Yu Hu2, Weigang Wang1, Yaowen Fu1. 1Urinary Diseases Diagnosis & Treatment Center, First Bethune Hospital of Jilin University, Changchun, China; 2Department of Pathology, China-Japan Union Hospital of Jilin University, Changchun, China.
Abstracts

52-OR
A FUNCTIONAL POLYMORPHISM IN FICOLIN-2 IN THE DONOR KIDNEY IS ASSOCIATED WITH IMPROVED RENAL TRANSPLANT OUTCOME.
Michael Eikmans¹, Ilse de Canck², Pieter van der Pol³, Carla C. Baan⁴, Geert W. Haasnoot¹, Marko J.K. Mallat⁵, Manon Bryson-Vergunst¹, Els de Meester², Joke I. Roodnat⁴, Jacqueline D.H. Anholts¹, Martine van Thielen⁵, Ilias I.N. Doxiadis¹, Hans W. de Fijter², Pieter J.E. van der Linden¹, Els van Beelen¹, Cees van Kooten³, Judith A. Kal-van Gestel⁴, Annemiek M.A. Peeters⁵, Willem Weimar⁴, Dave L. Roelen¹, Rudi Rossau⁵, Frans H.J. Claas¹. ¹Immunohematology, Leiden University Medical Center, Leiden, Netherlands; ²Innogenetics N.V., Ghent, Belgium; ³Nephrology, Leiden University Medical Center, Leiden, Netherlands; ⁴Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands.

53-OR
HLA CLASS I AND HLA-E INFLUENCE SUSCEPTIBILITY OF MULTIPLE MYELOMA CELLS TO ELIMINATION BY NK CELLS.
Lotte Wieten¹, Janine H.M.J. van Elssen², Subhashis Sarkar², Richard W. Groen³, Anton C.M. Martens³, Gerard M.J. Bos⁴, Marcel G.J. Tilanus¹. ¹Transplantation Immunology, Maastricht University Medical Center, Maastricht, Netherlands; ²Internal Medicine, Division of Haematology, Maastricht University Medical Center, Maastricht, Netherlands; ³Immunology, University Medical Center Utrecht, Utrecht, Netherlands.

54-OR
KIR-LIGAND MISMATCHES ARE ASSOCIATED WITH REDUCED LONG-TERM GRAFT SURVIVAL IN HLA FULLY COMPATIBLE KIDNEY TRANSPLANTATION.
Jeroen van Bergen¹, Alan Thompson¹, Geert W. Haasnoot¹, Joke J. Roodnat², Johan W. de Fijter³, Frans H.J. Claas¹, Frits Koning¹, Ilias I.N. Doxiadis¹. ¹Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; ²Division of Nephrology, Erasmus Medical Center, Rotterdam, Netherlands; ³Nephrology, Leiden University Medical Center, Leiden, Netherlands.

55-OR
NK CELL TRANSCRIPT EXPRESSION INDICATES THE DEGREE OF MICROSCLULAR DISEASE ACTIVITY IN LATE ANTIBODY MEDIATED REJECTION.
Luis G. Hidalgo¹, Banu Sis¹, Patricia M. Campbell¹, Phil Halloran². ¹Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ²Medicine, University of Alberta, Edmonton, AB, Canada.

56-OR
COMPREHENSIVE MAPPING (MULTI-ANALYTE-PROFILING) OF DONOR-SPECIFIC IMMUNE RESPONSIVENESS. A PROTEOMICS APPROACH.
Anat R. Tambur¹, Nancy D. Herrera¹, Kerry L. Ballard², Ralph L. McDade², Joshua Miller¹, Joe Leventhal¹. ¹Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA; ²Diagnostic Initiatives, Rules Based Medicine, Inc, Austin, TX, USA.
Abstracts

Tuesday, October 18, 2011
Poster Session
6:00 PM - 7:00 PM

1-P
ANTI-BW4 ANTIBODIES CAN MEDIATE POSITIVE CROSSMATCHES WITH DONORS TYPED AS BW4 NEGATIVE.
Patrick W. Adams, Annette Rearick, Aisha Eltayeb, Paula Steller, Nicholas DiPaola. Clinical Histo-compatibility Laboratory, The Ohio State University Medical Center, Columbus, OH, USA.

2-P
SOLID PHASE CROSSMATCH DEMONSTRATES 97% AGREEMENT WITH VIRTUAL CROSSMATCH.
Patrick W. Adams, Ronald P. Pelletier, Matthew Kott, Nicholas DiPaola. Tissue Typing, Ohio State University Medical Center, Columbus, OH, USA.

3-P
LUMINEX SINGLE ANTIGEN BEADS VS. PHENOTYPE BEADS FOR NON-HIGHLY SENSITIZED PATIENTS.
Moheeb A. Al-Awwami1, Fadi S. Al-Zayer1, Amal N. Algharbly1, Noura S. Abaalkhail1, Khalid A. Al-Meshari1,2. 1Histocompatibility and Immunogenetics Laboratory, King Faisal Specialist Hospital And Research Center, Riyadh, Saudi Arabia; 2Renal Transplant Unit, King Faisal Specialist Hospital And Research Center, Riyadh, Saudi Arabia.

4-P
DETECTION OF COMPLEMENT-FIXING ANTIBODIES SPECIFIC FOR DONOR LYMPHOCYTES AND ENDOTHELIAL PRECURSOR CELLS USING THE XM-ONE® CROSSMATCH TEST.
Mats Alheim1, Ayeda Mahri2, Jan Holgersson2. 1Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; 2Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

5-P
OPTIMIZED PRONASE TREATMENT ELIMINATES FALSE POSITIVE B CELL CROSSMATCH CAUSED BY DESSENSITIZATION PROTOCOL WITH RITUXIMAB: HIGH DOSE OF PRONASE TREATMENT AFFECTS CD19 EXPRESSION.
Gansuvd Balgansuren1, Linda Peel1, Tom Crews1, Adella Clark1, Barbara Burgess1, Wendy Wagnen1, Xiangmin Nie2, Patrick W. Adams3, Dong-Feng Chen1. 1Clinical Transplantation Immunology Laboratory, Duke University Medical Center, Durham, NC, USA; 2HLA Laboratory, Blood Center of Shandong Province, Jinan, Shandong Province, China; 3Tissue Typing Laboratory, The Ohio State University Medical Center, Columbus, OH, USA.
Abstracts

6-P
SPECTRUM OF ALLOSENSITIZATION FOLLOWING HOMOGRAFT IMPLANTATION.
Carol Bentlejewski¹, Brian Feingold², Steven Webber², Adriana Zeevi¹. ¹Pathology, University of Pittsburgh, Pittsburgh, PA, USA; ²Pediatric Cardiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA.

8-P
COMPLEMENT-DEPENDENT CYTOTOXICITY (CDC) TO DETECT HLA ANTIBODIES: OLD BUT GOLD.
Patricia Keiko Saito¹, Roger Haruki Yamakawa¹, Luciene Christina Marques Pereira da Silva², Waldir Veríssimo da Silva Júnior³, Sueli Donizete Borelli². ¹Program of Healthy Science, State University of Maringa, Maringa, Parana, Brazil; ²Basic Science of Healthy, State University of Maringa, Maringa, Parana, Brazil; ³Statistic, State University of Maringa, Maringa, Parana, Brazil.

9-P
IDENTIFICATION OF DENATURED CLASS II (DRB4) ANTIGENS ON SINGLE ANTIGEN BEADS.
Robert A. Bray¹, Howard M. Gebel¹, Jarhow Lee². ¹Pathology, Emory University, Atlanta, GA, USA; ²Research, One Lambda, Inc., Canoga Park, CA, USA.

10-P
SINGLE ANTIGEN BEADS REACH SATURATION AT ANTIBODY LEVELS THAT DO NOT SATURATE LYMPHOCYTES IN THE FLOW CYTOMETRIC CROSSMATCH.
Robert A. Bray, Lisa A. Coleman, Patricia E. Brannon, Howard M. Gebel. Pathology, Emory University, Atlanta, GA, USA.

11-P
SEREOLOGICAL EVIDENCE FOR THREE DISTINCT SUB-EPITOPES OF BW6.
Robert A. Bray, Howard M. Gebel. Pathology, Emory University, Atlanta, GA, USA.

12-P
SOLUBLE HLA COUPLED LUMINEX BEADS.
Rico Buchli¹, William Hildebrand², Steven Cate². ¹Pure Transplant Solutions, Pure Protein L.L.C., Oklahoma City, OK, USA; ²Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Abstracts

13-P
PRONASE TREATMENT OF LYMPHOCYTES INDUCES NONSPECIFIC COMPLEMENT SENSITIVITY.
Kevin M. Burns1, Todd N. Eagar2, Fleur Aung3, Robert G. O’Brien1, Geoff A. Land1. 1Pathology and Laboratory Medicine - HLA, The Methodist Hospital, Houston, TX, USA; 2Pathology and Laboratory Medicine - HLA, University of Texas Southwestern Medical Center, Dallas, TX, USA; 3Laboratory Medicine - HLA, M.D. Anderson Cancer Center, Houston, TX, USA.

14-P
DISCORDANCE BETWEEN FLOW CYTOMETRIC CROSSMATCH RESULTS AND THE DETECTION OF DONOR-SPECIFIC ANTIBODY OF THE “B4402/4403/45/76/82” SPECIFICITY GROUP BY LUMINEX SINGLE ANTIGEN.
Margaret Chambers, Laurie Voit, Sandy Dunaway, Jane Duenas-Dominguez, Thai Lee, Rosa Aguirre-Chavez, Barbara Masten. HLA, TriCore Reference Laboratories, Albuquerque, NM, USA.

15-P
TECHNICAL VARIATIONS OF LUMINEX SINGLE ANTIGEN BEAD ASSAY USED FOR HLA ANTIBODY IDENTIFICATION AND DESENSITIZATION MONITORING.
Xiangmin Nie1 3, Chih-Hung Lai2, Balgansuren Gansuvd1, Jennifer Deitz1, Linda Peel1, Adella Clark1, Giles Crows1, Barbara O. Burgess1, Wendy E. Wegner1, Dong-Feng Chen1. 1Clinical Transplantation Immunology Lab, Duke University Medical Center, Durham, NC, USA; 2HLA Laboratory, Cedars-Sinai Health Systems, Los Angeles, CA, USA; 3HLA Lab, Blood Center of Shandong Province, Jinan, Shandong, China.

16-P
EVALUATION OF THE NorDiag Arrow INSTRUMENT FOR T AND B LYMPHOCYTE ISOLATION.
Kevin A. Chesterton, Melissa E. Jeresano, Jennifer L. Metz, Mary S. Leffell, Andrea A. Zachary. School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

17-P
LUMINEX SOLID PHASE TESTING IMPROVES IDENTIFICATION OF NON SENSITIZED TRANSPLANT RECIPIENTS AS DEMONSTRATED BY BETTER GRAFT FUNCTION.
Robert Cirocco, Kristen Gilbert, Lindsey Bionde, Michael Moritz. Transplant Center, Lehigh Valley Health Network, Allentown, PA, USA.

18-P
CORRELATION OF FLOW CROSSMATCH STRENGTH WITH HLA ANTIBODY MFI VALUES.
Deborah O. Crowe1, Christina D. Bishop2, Nichole B. Barton2. 1Transplant Immunology, DCI Laboratory- Nashville, Nashville, TN, USA; 2Transplant Laboratory, DCI Laboratory- Knoxville, Knoxville, TN, USA.
Abstracts

19-P
EXAMINING VARIABILITY IN UNACCEPTABLE ANTIGEN CALLS BETWEEN HISTOCOMPATIBILITY LABS WITHIN A GIVEN UNOS REGION: A SHARING AMONG FRIENDS.
Nicholas R. DiPaola¹, Dorothy M. Levis³, Gary A. Teresi⁴, Nancy Higgins². ¹Surgery, OSU Medical center, Columbus, OH, USA; ²Histocompatibility Lab, Indiana University Health Methodist, Indianapolis, IN, USA; ³Histocompatibility, Gift of Life Michigan, Ann Arbor, MI, USA; ⁴Allogen Labs, Cleveland, OH, USA.

20-P
CHALLENGING THE DEFINITION OF DONOR SPECIFIC ANTIBODIES: TOO MUCH ABOUT NOTHING?
Yvonne M. Zoet¹, Simone H. Brand-Schaaf¹, Angeliki Vittoraki², Dave L. Roelen¹, Arend Mulder¹, Frans H.J. Claas¹, ³, Ilias I.N. Doxiadis¹, ³. ¹Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; ²National Tissue Typing Center, Hospital Genimatas, Athens, Greece; ³Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, Netherlands.

21-P
PERIPHERAL BLOOD LYMPHOCYTES FROM INDIVIDUAL TYPED AS HLA-DQB1*03:21 DO NOT BIND ANTIBODIES TO HLA-DQ3, DQ7, DQ8 OR DQ9 BY FLOW CYTOMETRY.
Arthur B. Eisenbrey, Sharon M. Skorupski. Transplant Immunology, Henry Ford Hospital, Detroit, MI, USA.

22-P
DIAGNOSTIC ACCURACY OF SOLID PHASE ANTIBODY ASSAYS FOR PREDICTION OF CELL-BASED CROSSMATCHES ASSESSED USING RECEIVER OPERATING CURVE (ROC) ANALYSIS.
Thomas M. Ellis¹,², Karen L. Pierce¹, Christopher P. Johnson², Jennifer J. Schiller¹. ¹Histocompatibility and Immunogenetics, BloodCenter of Wisconsin, Milwaukee, WI, USA; ²Transplant Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.

23-P
EVALUATION OF HLA TYPING BY REAL-TIME PCR.
Mohamed Elrefaei, John Vrnak, John Crawford, John L. Schmitz. Histocompatibility Laboratory, McLendon Clinical Laboratories, University of North Carolina Hospitals, Chapel Hill, NC, USA.

24-P
FLOW CYTOMETRIC CROSSMATCHING COMPARING AN AUTOMATED CELL WASHER AND A TUBE METHOD FOR WASHING AND INCUBATION.
Deborah K. Falbo, Steven R. De Goey, Sarah H. Jenkins, Manish J. Gandhi. Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Abstracts

25-P
HLA ANTIBODIES THAT ARE NOT DETECTED BY THE C1q SCREEN TM CAN FIX COMPLEMENT AND ARE CLINICALLY SIGNIFICANT.
Anne Fuller², Kevin Williams², Denise Hurst², Lori Ellinger², David D. Eckels¹. ¹Pathology, University of Utah, Salt Lake City, UT, USA; ²Histocompatibility Lab, University of Utah, Salt Lake City, UT, USA.

26-P
INTER AND INTRA LABORATORY CONCORDANCE OF HLA ANTIBODY RESULTS OBTAINED BY SOLID PHASE ASSAY.
Manish J. Gandhi¹, Steven R. DeGoey¹, Deborah Falbo¹, James R. Stubbs¹, David F. Lorentzen², Harriet Noreen³, JarHow Lee⁴. ¹Division of Transfusion Medicine and Division of Transplantation, Mayo Clinic, Rochester, MN, USA; ²Pathology, University of Wisconsin Hospitals & Clinics, Madison, WI, USA; ³Pathology, Fairview University Medical Center, Minneapolis, MN, USA; ⁴One Lambda Inc, Canoga Park, CA, USA.

27-P
TOWARD VIRTUAL CROSSMATCH IN CALGARY: ASSESSMENT OF SPECIFICITY AND SENSITIVITY OF A SOLID PHASE ASSAY IN PREDICTING CDC-AHG AND FLOW CYTOMETRY CROSSMATCHES.
Salim Gandorah¹, Faisal M. Khan¹.².³, Sansira Seminowich⁴, Abdelhamid Liacini¹.², Iwona Galaszkiewicz¹, Luz Stamm¹, Mauricio Monroy-Cuadros⁵, Serdar Yilmaz⁴, Noureddine Berka¹.². ¹Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada; ²Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; ³Paediatrics, University of Calgary, Calgary, Canada; ⁴Transplantation, University of Calgary, Calgary, Canada.

29-P
HEATING THE SERUM AT 56ºC FOR ONE MINUTE SOLVES THE PROBLEM OF INHIBITORY FACTORS IN THE LUMINEX ANTIBODY DETECTION ASSAYS.
Renato de Marco¹, Amador Goncalves-Primo¹, Érika F. Campos¹.², Maria Gerbase-DeLima¹.². ¹Immunogenetics, Associação Fundo de Incentivo à Pesquisa, São Paulo, SP, Brazil; ²Universidade Federal de São Paulo, São Paulo, SP, Brazil.

30-P
DIFFERENTIAL ANTIGEN- AND EPITOPE-BASED REDUCTION OF HLA-SPECIFIC ANTIBODY IN RENAL TRANSPLANT CANDIDATES UNDER PROTEASOME INHIBITOR-BASED DESENSITIZATION.
Abstracts

31-P
THE IMPACT OF POSITIVE FLOW CYTOMETRY CROSSMATCH RESULTS ON LATE RENAL ALLOGRAFT SURVIVAL.
Ralph J. Graff1, Huiling Xiao1, Arsalan Siddiqui1, Brian Duffy2, Krista L. Lentine1. 1HLA Laboratory, Saint Louis University, St. Louis, USA; 2HLA Laboratory, Barnes Hospital, St. Louis, USA.

32-P
DTT TREATMENT: TO DO OR NOT TO DO (ROUTINELY), THAT IS THE QUESTION.
Anne Halpin, Newson Ly, Luis Hidalgo, Patricia Campbell. Histocompatibility Laboratory, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada.

33-P
SEARCH FOR CLINICAL RELEVANCE OF ANTIBODY DETECTION.
Vera Hauptfeld-Dolejsek, Zhuo Tao. Alabama Regional Histocompatibility Laboratory, University of Alabama at Birmingham, Birmingham, AL, USA.

34-P
IDENTIFICATION OF AN ANTIBODY TO HLA-A*02 ALLELES IN A PATIENT WHO TYPES FOR HLA-A*02:02.
Sandra W. Helman1,2. 1Surgery and Cell Biology and Anatomy, Georgia Health Sciences University, Augusta, GA, USA; 2Histocompatibility/Immunology Laboratory, MCG Health System, Augusta, GA, USA.

35-P
EFFECTS OF CRYOPRESERVATION AND PRONASE TREATMENT ON HLA CLASS I AND II SURFACE EXPRESSION.
Danny Chau1, Luis G. Hidalgo1, Anne Halpin2, Patricia M. Campbell1. 1Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; 2UAH - Histocompatibility Laboratory, Alberta Health Services, Edmonton, AB, Canada.

36-P
DEFINING ACCEPTABLE MISMATCHES IN THE PRESENCE OF LUMINEX ANTIBODY REACTIVITY.
Fiona Hudson1, Linda Cantwell1, Alan Boyle1, Shlomo Cohney2, Mary Diviney1, Rhonda Holdsworth1. 1Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Victoria, Australia; 2Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia; 3Medical and Quality Services, Australian Red Cross Blood Service, Melbourne, Victoria, Australia.
Abstracts

37-P
SIGNIFICANT INCREASE OF KIDNEY TRANSPLANTS IN HIGHLY SENSITIZED PATIENTS BY IMPLEMENTATION OF THE VIRTUAL CROSSMATCH.
Andres Jaramillo1, Martin D. Jendrisak1, Bozena Labuda1, John Turon1, David Freedom1, Daniel Magas1, Lawrence J. Jennings2, Sivadasan Kanangat3, Fritz Lower4, Brian Susskind5, Susana R. Marino6, Sujata Gaitonde7, Anat R. Tambur8. 1Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA; 2Dept. of Pathology, Children’s Memorial Hospital, Chicago, IL, USA; 3Dept. of Pathology, Rush University, Chicago, IL, USA; 4Department of Pathology, Memorial Medical Center, Springfield, IL, USA; 5Dept. of Pathology, Loyola University, Maywood, IL, USA; 6Dept. of Pathology, University of Chicago, Chicago, IL, USA; 7Dept. of Pathology, University of Illinois at Chicago, Chicago, IL, USA; 8Dept. of Surgery, Northwestern University, Chicago, IL, USA.

38-P
ASSIGNING A PUBLIC EPITOPE ANTIBODY – WHAT IS THE BEST CUTOFF METHOD TO USE?
Peter T. Jindra1, Don M. Constantino1, David J. Conti2, Michael Gallichio2, Nicole Siparsky2, Amy B. Hahn1. 1Transplant Immunology Laboratory, Department of Surgery, Albany Medical College, Albany, NY, USA; 2Section of Transplantation, Department of Surgery, Albany Medical College, Albany, NY, USA.

39-P
DISCREPANT REACTIVITY OF ANTI-DQA/DQB ANTIBODY WITH SINGLE ANTIGEN BEADS VERSUS PERIPHERAL BLOOD B CELLS: IMPLICATIONS FOR THE ASSESSMENT OF DONOR SPECIFIC ANTIBODY AND DONOR SELECTION.
Jane Kearns, Thanh-Mai Bui, Malek Kamoun. Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

40-P
CORRELATION BETWEEN SOLID PHASE TESTS: XM VS ANTIBODY SCREEN.
Denise E. Kielek, Karl P. Schillinger, Donna P. Lucas, Mary S. Leffell, Andrea A. Zachary. Medicine, Johns Hopkins University, Baltimore, MD, USA.

41-P
DEDUCTION OF MISMATCHED DONOR HLA FROM FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE SAMPLES OF RENAL TRANSPLANT RECIPIENTS.
Janette Kwok1, Gavin S.W. Chan2, M.F. Lam3, Ricky Lau1, Lydia Tang4, W.K. Lee1, K.W. Chan2, TM Chan3. 1Transplantation and Immunogenetics, Pathology and Clinical Biochemistry, Queen Mary Hospital, Hong Kong SAR, China; 2Pathology, The University of Hong Kong, Hong Kong SAR, China; 3Medicine, The University of Hong Kong, Hong Kong SAR, China.
Abstracts

42-P
BIOLOGICAL AND CLINICAL RELEVANCE OF THE LUMINEX CROSSMATCH: A SINGLE CENTER STUDY OF 117 KIDNEY TRANSPLANT RECIPIENTS.
Elena Lazarova¹, Anne Lemy², Marc Andrien¹, Daniel Abramowicz², Michel Toungouz¹. ¹Hematology Transfusion, Erasme Hospital, HLA Laboratory, Brussels, Belgium; ²Nephrology Department, Erasme Hospital, Renal Transplantation Clinic, Brussels, Belgium.

43-P
WEAKLY REACTIVE PRE-TRANSPLANT DSA COMBINED WITH STRINGENT FINAL CROSS-MATCH ARE NOT ASSOCIATED WITH ADVERSE SHORT TERM KIDNEY TRANSPLANT OUTCOMES.
Matthew H. Levine¹, Alexander R. Bonnel¹, Jane Kearns², Peter Yoo¹, Malek Kamoun². ¹Surgery, University of Pennsylvania, Philadelphia, PA, USA; ²Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

44-P
COMPARISON OF ANALYSIS METHODS FOR ESTABLISHING CUT-OFF VALUES FOR SOLID-PHASE ANTI-HLA ANTIBODY TESTING.
Chang Liu¹, Sue Pang², Donna L. Phelan², Thalachallour Mohanakumar¹,², Gerald P. Morris¹. ¹Department of Pathology and Immunology, Washington University, St. Louis, MO, USA; ²Barnes-Jewish Hospital, St. Louis, MO, USA.

45-P
AN OPTIMIZED FLOW CYTOMETRIC CROSSMATCH ASSAY EXPEDITES PRE-TRANSPLANT IMMUNOLOGIC RISK ASSESSMENT.
Robert Liwski¹, Geoff Adams¹, Geoff Peladeau¹, David Eckels², Robert Bray³, Howard Gebel³. ¹Department of Pathology, Dalhousie University, Halifax, NS, Canada; ²Department of Pathology, University of Utah, Salt Lake City, UT, USA; ³Department of Pathology, Emory University, Atlanta, GA, USA.

46-P
SUCCESSFUL KIDNEY TRANSPLANTATION (KT) AGAINST POSITIVE FLOW CYTOMETRY (FC) CROSS MATCH (CM) CAUSED BY DONOR SPECIFIC ANTIBODIES (DSA) WITHOUT INTENSIVE IMMUNOMODULATION.
Andrew L. Lobashevsky¹, William Goggins², Timothy Taber²,³, Nancy G. Higgins¹. ¹Histocompatibility Laboratory, Indiana University Health, Methodist Hospital, Indianapolis, IN, USA; ²Surgery, Indiana University School of Medicine, Indianapolis, IN, USA; ³Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstracts

47-P
C1q BINDING DONOR SPECIFIC HLA ANTIBODY MONITORING BY LUMINEX SINGLE ANTIGEN ASSAY IS USEFUL IN PREDICTING CLINICAL EVENTS.
John G. Lunz¹, Steven Webber², Kyle Soltys³, Ron Shapiro³, Jeffery Teuteberg³, Brian Feingold², Matthew Morrell³, Larry Jelinek¹, Adriana Zeevi¹. ¹Pathology, University of Pittsburgh, Pittsburgh, PA, USA; ²Cardiology, Childrens Hospital of Pittsburgh, Pittsburgh, PA, USA; ³Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

48-P
XM-ONE® DOES NOT ALLOW THE DETECTION OF ANTI MICA ANTIBOIES.
Anne McIlroy, Sylvie Cury, Maryluc Cheneau, Anne Devys, Anne Cesbron. Laboratoire HLA, Etablissement Français du Sang, Nantes, France.

49-P
HOW MUCH IS TOO MUCH.
Jennifer L. Mendiolina, Robert Cirocco, Michael Moritz. HLA Lab, Lehigh Valley Health Network, Allentown, PA, USA.

50-P
SINGLE ANTIGEN BEAD (SAB)(NORMAL AND “CLEAN” BEADS) MFI THRESHOLD FOR DONOR SPECIFIC ANTIGEN (DSA), COMPARED TO FLOW AND CYTOTOXIC CROSSMATCH RESULT.
Derek Middleton¹, James Jones¹, Matthew Howse², Pam Beales¹, Chang Seng Wong³, Abdul Hammad². ¹Transplant Immunology, Royal Liverpool Hospital, Liverpool, United Kingdom; ²Transplant and Nephrology Centre, Royal Liverpool Hospital, Liverpool, United Kingdom.

51-P
SINGLE ANTIGEN BEAD (SAB) ASSAYS OF ANTI-HLA ANTIBODY COMBINED WITH EPI TOPE ANALYSIS IMPROVES VIRUAL CROSS MATCH AND UNACCEPTABLE ANTIGEN ASSESSMENT.
Allen J. Norin¹, Ballabh Das¹, David Hochman¹, Moro Salifu². ¹Transplant Immunology & Immunogenetics, SUNY Downstate Medical Center, Brooklyn, NY, USA; ²Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA.

52-P
A SPECIALIZED TUBE TO MAKE ROSETTSEP™ CELL ENRICHMENT FASTER AND EASIER.
Abstracts

53-P
WHICH IS THE CLINICALLY RELEVANT ANTIBODY IN PATIENTS WAITING FOR TRANSPLANTATION: LUMINEX SAB SCREENS VERSUS C1q ASSAYS?
Donna L. Phelan1, Kevin Harrell1, David Clark1, T. Mohanakumar2. 1Laboratories, Barnes-Jewish Hospital, St. Louis, MO, USA; 2Surgery, Washington University School of Medicine, St. Louis, MO, USA.

54-P
VIRTUAL CROSSMATCH AND CLINICAL RELEVANCE OF HLA ANTIBODIES DETECTED BY LUMINEX-SINGLE ANTIGEN BEADS.
Antonina Piazza1, Elvira Poggi1, Daniela Caputo2, Giuseppina Ozzella1, Rosa Cremona2, Valentina Imbroglini2, Anna Rita Manfreda2, Luisa Mazzitelli2, Domenico Adorno2. 1Regional Transplant Center - Lazio, National Council of Researches, IFT Unit of Roma S. Camillo, Rome, Italy; 2Regional Transplant Center - Lazio, “Tor Vergata” University of Rome, Rome, Italy.

55-P
MOLECULAR SIZE EXCLUSION USING MEMBRANE FILTERS IS EFFECTIVE FOR CORRECTING THE ABNORMAL MFI THAT CONFOUND DSA INTERPRETATION.
Blanca M. Ponce1, Rex A. Friedlander1, Arvind K. Menon1, Don Constantino3, Felipe Diaz1, Darshana Dadhania1,2, Vijay K. Sharma1,2, Manikkam Suthanthiran1,2. 1Immunogenetics and Transplantation Laboratory, The Rogosin Institute, New York, NY, USA; 2Department of Transplantation Medicine, NYU-Weill Cornell Medical Center, New York, NY, USA; 3Transplantation Immunology Laboratory, Albany Medical College, Albany, NY, USA.

56-P
CONCORDANCE OF ANTIBODY PROFILE AND CROSSMATCH IN POTENTIAL KIDNEY RECIPIENTS.
Michael J. Rewinski, Maureen M. Miller, Tod V. Alberghini, David O’Sullivan, Laurine Bow, David Hull. Transplant Immunology, Hartford Hospital, Hartford, CT, USA.

57-P
SPIN COLUMNS ELIMINATE INTERFERENCE IN LUMINEX SINGLE ANTIGEN ANTIBODY ASSAY.
Michael J. Rewinski, Maureen M. Miller, Tod V. Alberghini, Laurine Bow, David Hull. Transplant Immunology, Hartford Hospital, Hartford, CT, USA.

58-P
DETECTION OF C1Q-FIXING ANTIBODIES CORRELATES WITH AHG-COMPLEMENT DEPENDENT CYTOTOXICITY CROSSMATCH RESULTS.
Cecil L. Rhodes, Nancy Mata, Placida Abes, Prakash Rao. Transplant Laboratory, New Jersey Organ and Tissue Sharing Network, New Providence, NJ, USA.
Abstracts

59-P
EFFECT OF ADSORPTION WITH FETAL CALF SERUM ON UNEXPECTED POSITIVE FLOW CYTOMETRY CROSSMATCH RESULTS.
Cecil L. Rhodes, Nancy Mata, Prakash Rao. Transplant Laboratory, New Jersey Organ and Tissue Sharing Network, New Providence, NJ, USA.

60-P
COMPARISON OF LABSCAN 100 FOUR WASH METHOD TO LABXPRESS THREE WASH METHOD: EFFECT OF PROZONE ON QUANTITATIVE EVALUATION OF MFI.
Cecil L. Rhodes, Nancy Mata, Prakash Rao. Transplant Laboratory, New Jersey Organ and Tissue Sharing Network, New Providence, NJ, USA.

61-P
VACCINE INDUCED allo-HLA REACTIVE MEMORY T-CELLS IN A KIDNEY TRANSPLANTATION CANDIDATE.
Lloyd J.A. D’Orsogna1, Dave L. Roelen1, Ellen M.W. van der Meer-Prins1, Nicole M. van Besouw2, Pieter van der Pol3, Marry Franke-van Dijk1, Yvonne M. Zoet1, Arno van der Slik1, Willem Weimar2, Cees van Kooten1, Ilias I.N. Doxiadis1. 1Dept. of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 2Dept. of Internal Medicine, Erasmus MC, Rotterdam, Netherlands; 3Dept. of Nephrology, LUMC, Leiden, Netherlands.

62-P
xHLA SOFTWARE – SHORTER TIME AND HIGHER ACCURACY IN DETERMINING ACCEPTABLE MISMATCHES FOR TRANSPLANTATION.
Herton L.A. Sales Filho1, Luiz Claudio D.M. Sousa1, Evelin N.S. Edlin1, Fernanda S.L. Moura1, Janine M.F. Watanabe1, Juliane R.D. Torres1, Laiane C. Lopes1, Lexasilva A.L. Barros1, Carolina Kneib3, Daniele M. Kitamura3, Helena B. Cazarote1, Liliane M. Nascimento1, Carlos F. Alves3, Pedro A. Santos Neto2, Michelle F. Susin1, Adalberto S. Silva1, Cristina Q.C. Von Glehn3, Semiramis J.H. Monte1. 1Imunogenetics and Molecular Biology Laboratory, Federal University of Piauí, Teresina, Brazil; 2Department of Informatics and Statistics, Federal University of Piauí, Teresina, Brazil; 3Immunogenetics Laboratory, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.

63-P
THE RELEVANCE OF PRE-TRANSPLANT SOLUBLE HLA-G LEVELS AND/OR DONOR SPECIFIC HLA ANTIBODIES ON RENAL ALLOGRAFT SURVIVAL.
Jerome G. Saltarrelli1, Laszlo A. Bihari1, Jacqueline A. Lappin1, Stephen M. Katz1, Karoly Varga1, Charles T. Van Buren1, Carol Bentlejewski2, Daniel J. Cook1, Adriana Zeevi2, Ronald H. Kerman1. 1Surgery-Organ Transplantation, University of Texas Medical School at Houston, Houston, TX, USA; 2Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abstracts

64-P
NO DTT TREATMENT FOR FLOW CROSSMATCH (XM).
Justine L. Gaspari, Lori A. Malec, Margaret A. Maybach, Kimberly J. Goss, Dennis F. Habig, Tom L. Bement, Jenn L. Tyler, Heather A. Casey, Ronald E. Domen, Lorie H. Kumer, Hiroko Shike. Pathology, HLA laboratory, Penn State Hershey Medical Center, Hershey, PA, USA.

65-P
PREDICTING CROSSMATCH (XM) RESULTS; ASHI PROFICIENCY TESTING (PT) RESULTS AS A MAIN SOURCE OF ASSAY CORRELATION.
Justine L. Gaspari, Heather A. Casey, Lorie H. Kumer, Carolyn L. Fisher, Michele E. Lachance, Dorothy K. Felt, Jean A. Hess, Carrie L. Mowery, Ronald E. Domen, Hiroko Shike. Pathology, HLA laboratory, Penn State Hershey Medical Center, Hershey, PA, USA.

66-P
ANTIBODIES AS DEFINED BY THE x-MAP TECHNOLOGY, ANTIBODY-MEDIATED REJECTION AND SURVIVAL OF THE KIDNEY ALLOGRAFT.
Eva Slimackova1, Ondrej Viklicky2, Yelena Pavlova1, Janka Slatinska2, Marcela Bürgeleva2, Eva Honsova1, Alena Lodererova3, Antonij Slavcev1. 1Department of Immunogenetics, IKEM, Prague, Czech Republic; 2Department of Nephrology, IKEM, Prague, Czech Republic; 3Department of Pathology, IKEM, Prague, Czech Republic.

67-P
HOW ACCURATELY ARE WE IDENTIFYING ANTIBODIES ON HIGHLY SENSITIZED PATIENTS?
Luz A. Stamm, Kimberley Larlee, Iwona Galaszkiewicz, Charlene Ott, Noureddine Berka. Tissue Typing, Calgary Laboratory Services, Calgary, AB, Canada.

68-P
DRB1*08 WITH DRB3*????? – TYPING ENCOUNTERED DURING DECEASED DONOR WORKUP.
Teri-Lynn Steeves, Lisa Harper, Rosanna Doto. Histocompatibility, McMaster University Medical Centre, Hamilton, ON, Canada.

69-P
ROLE OF DONOR SPECIFIC ANTI-ENDOTHELIAL ANTIBODIES PRE TRANSPLANT IN LIVING DONOR KIDNEY TRANSPLANTATION. A SINGLE CENTER STUDY.
Anat R. Tambur, Jennifer Wehner, Shivani Shah, Charles Jie, Wendey Wegner, Joe Leventhal, John Friedewald. Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA.
Abstracts

70-P
INVESTIGATION OF ALLONANTIBODIES DEVELOPED FOLLOWING INFLUENZA VACCINATION.
Patricia A. Willey1, D. Phelan1, G.P. Morris2, T. Mohanakumar2,3. 1HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; 2Dept. of Pathology and Immunology, Washington University, St. Louis, MO, USA; 3Dept. of Surgery, Washington University, St. Louis, MO, USA.

71-P
TRENDS IN KIDNEY TRANSPLANTATION ACROSS A POSITIVE CROSSMATCH: THE UNOS DATA.
Isabelle G. Wood, Edgar L. Milford, Indira Guleria. Tissue Typing Laboratory, Brigham and Women’s Hospital, Boston, MA, USA.

72-P
PRE-TRANSPLANT HLA-DSA THAT PERSIST POST-TRANSPLANT PREDICT INCREASED RISK OF ANTIBODY-MEDIATED REJECTION AND GRAFT LOSS IN RENAL TRANSPLANTATION.
Patrizia Amico1,2, Nubia Banuelos3, Gideon Höniger1, Helmut Hopfer4, Stefan Schaub1, Paul I. Terasaki2. 1Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland; 2Research, Terasaki Foundation Laboratory, Los Angeles, CA, USA; 3Research II, One Lambda Inc., Canoga Park, CA, USA; 4Institute for Pathology, University Hospital Basel, Basel, Switzerland.

73-P
A NEW HISTOCOMPATIBILITY APPROACH TO DEAL WITH TRANSPLANT TOURISM CHALLENGES USING DNA EXTRACTED FROM KIDNEY BIOPSY TISSUE TO AID IN POSTTRANSPLANT GRAFT MONITORING AND ASSESSMENT OF THE RISK FOR REGRAFT.
Mohammed I. Awaji1, Faisal M. Khan3,4,5, Mohammad M. Mohammad1, Masood Al Qahtani1, Dalal H. Al-Abduladheem1, Ahmed S. Al-Otaibi1, Abdurrahman Housawi2, Mohammed Sagheir2, Mohammed Gonaim2, Mohammed Alqahtani2, Nouredine Berka3,4. 1Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada; 3Multi-Organ Transplant Center, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 4Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; 5Paediatrics, University of Calgary, Calgary, Canada.

74-P
A URINARY BIOMARKER ASSAY IN CLINICAL PRACTICE.
Kimberly N. Beane, Jennie W. Stewart, David F. Kiger, Jeff Rogers, Michael D. Gautreaux. General Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstracts

75-P
KIR2DS2 AND KIR2DS4 GENE EXPRESSION IN KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT ACUTE REJECTION.
Marcio Marques de Moraes, Maria da Graça Bicalho. Departamento de Genética, Laboratório de Imunogenética e Histocompatibilidade da Universidade Federal do Paraná, Curitiba, Paraná, Brazil.

76-P
ONLY IgG1 ANTIBODIES AGAINST HLA AND MICA ARE SIGNIFICANTLY ASSOCIATED WITH RENAL GRAFT FAILURE: RESULTS OF A FOUR-YEAR COHORT STUDY.
Junchao Cai1, Paul I. Terasaki1, Nils Lachmann2, Fay M. Jahr1, Constanze Schonemann2. 1R&D, Terasaki Foundation Laboratory, Los Angeles, USA; 2HLA Lab, Charité-Universitätsmedizin, Berlin, Germany.

77-P
POST TRANSPLANT CPRA AND DSA MONITORING IDENTIFIES SENSITIZED RENAL TRANSPLANT RECIPIENTS THAT EXHIBIT IMPROVED GRAFT FUNCTION.
Robert Cirocco, Kristin Gilbert, Jennifer Mendiolina, Marilyn Wetmore, Patricia Kimble, Linsey Biondi, Michael Mortiz. Transplant Center, Lehigh Valley Health Network, Allentown, PA, USA.

78-P
ESCAPING THE MFI TRAP: DSA VERSUS NDSA REACTION PATTERNS TO ASSESS RISK OF GRAFT FAILURE BY AMR.
Cristina de Queiroz Carrascosa von Glehn1, Liliane Machado Nascimento 1, Bruna Paladino Vieira1, Ana Carolina Sasaki1, Fabiana Loss Contieri2, Carolina Pozzi2, Luciane Monica Deboni3, Michelle Fernanda Susin1. 1Transplant Immunology Laboratory, Pontifical Catholic University of Parana - PUCPR, Curitiba, Paraná, Brazil; 2Kidney Transplant, Evangelic Hospital of Curitiba, Curitiba, Paraná, Brazil; 3Transplant, Kidney Foundation of Santa Catarina, Joinville, Santa Catarina, Brazil.

79-P
DETERMINATION OF A SINGLE ANTIGEN BEAD MFI CUTOFF FOR DE NOVO DSA BASED ON 10 YEAR OUTCOMES OF A LONGITUDINALLY STUDIED RENAL TRANSPLANT POPULATION.
Matthew J. Everly1, Lorita M. Rebellato2, Mikki Ozawa1, Kimberly P. Briley2, Paul G. Catrou2, Carl E. Haisch2, Paul I. Terasaki3. 1Research II, One Lambda Inc, Los Angeles, CA, USA; 2Brody School of Medicine, East Carolina University, Greenville, NC, USA; 3Terasaki Foundation, Terasaki Foundation, Los Angeles, CA, USA.
Abstracts

80-P
A MORE SENSITIVE HALLMARK OF ACUTE REJECTION (AR) AFTER RENAL TRANSPLANTATION: COLOR DOPPLER ULTRASONOGRAPHY OF RENAL PYRAMIDS.
Baoshan Gao, Yuantao Wang, Gang Wang, Yaowen Fu. First Bethune Hospital of Jilin University, Urinary Diseases Diagnosis & Treatment Center, Changchun, China.

81-P
EVALUATION OF TLR4 mRNA BLOOD LEVELS AND TLR4 GENOTYPES AS TOOLS TO ESTIMATE RISK OF DELAYED GRAFT FUNCTION.
Vinicius Andrade-Oliveira¹,², Erika F. Campos¹,², Amador Goncalves-Primo¹, Patricia C. Grenzi¹,², Tuila B. Mourao¹,², Jose O. Medina-Pestana²,³, Helio Tedesco-Silva³, Maria Gerbase-DeLima¹,². ¹Immunogenetics Institute, Associação Fundo de Incentivo à Pesquisa, São Paulo, SP, Brazil; ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil; ³Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, São Paulo, SP, Brazil.

82-P
OUTCOME OF SIMULTANEOUS LIVER KIDNEY TRANSPLANT (SLKT) ACROSS A FLOW POSITIVE CROSSMATCH.
Vera Hauptfeld-Dolejsek¹, Vineeta Kumar², Zhuo Tao¹. ¹Alabama Regional Histocompatibility Laboratory, University of Alabama at Birmingham, Birmingham, AL, USA; ²Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.

83-P
CYLEX IMMUNE FUNCTION ASSAY IN HEART TRANSPLANTATION.
Eric Ho¹, Zhuoru Liu¹, George Vlad¹, Nicole Suciu-Foca¹, Adriana Colovai¹, Susan Restaino², Donna Mancini². ¹Pathology and Cell Biology, Columbia University, New York, NY, USA; ²Medicine, Columbia University, New York, NY, USA.

84-P
LOOKING LONGITUDINALLY: SERIAL CYLEX ImmuKnow TESTING AND PATIENT HISTORY BETTER DEMONSTRATE CLINICAL EVENT IN RENAL ALLOGRAFT RECIPIENTS.
John G. Lunz¹, Elizabeth Greiner-Sosanko¹, Heinke Tan², Amit Basu², Ron Shapiro², Adriana Zeevi¹. ¹Pathology, University of Pittsburgh, Pittsburgh, PA, USA; ²Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

85-P
NEAR NORMAL ImmuKnow RESPONSES IN HLA IDENTICAL RENAL TRANSPLANT RECIPIENTS GIVEN DONOR HEMATOPOETIC STEM CELLS AND ALEMTUZUMAB DESPITE PROFOUND T CELL DEPLETION.
James M. Mathew¹,², Joseph Leventhal¹, John Friedewald¹, Josh Levitsky¹, Jane Charette¹, Li Chen¹, Dhivya Chandrasekaran¹, Anat Tambur¹, Joshua Miller¹,². ¹Comprehensive Transplant Center, Northwestern University, Chicago, USA; ²Research, Jesse Brown VA Medical Center, Chicago, IL, USA.
Abstracts

86-P
INFLAMMATORY CYTOKINE RELEASE SIGNALS THROUGH TLR-2 AND TLR-4 IN RENAL ALLOGRAFT TRANSPLANTATION.

D. Olga McDaniel¹, Debbie Rigney², W. Jordan Windham², Kori McDaniel², Alan Hawxby¹, Fauzia Butt¹. ¹Surgery, University of Mississippi Medical Center, Jackson, MS, USA; ²School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

87-P
POST-TRANSPLANT DETECTION OF A DONOR SPECIFIC (EPITOPE) ANTIBODY RESULTING IN A POSITIVE FLOW CROSSMATCH.

Maureen M. Miller, Tod V. Alberghini, Michael Rewinski, Laurine M. Bow. Transplant Immunology Laboratory, Hartford Hospital, Hartford, CT, USA.

88-P
ANTI-HLA ANTIBODY REDUCED GRAFT SURVIVAL IN LIVING-RELATED TRANSPLANTS.

Kazuo Mizutani¹, Ryohei Hattori¹, Tsuneo Kinukawa², Momokazu Gotoh¹. ¹Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; ²Urology, Chukyo Hospital, Nagoya, Aichi, Japan.

89-P
SIGNIFICANCE OF C1q-FIXING DONOR SPECIFIC ANTIBODIES (DSA) FOLLOWING HUMAN LUNG TRANSPLANTATION.

Donna L. Phelan¹, Kevin Harrell², Elbert Trulock², Ramsey Hachem², T. Mohanakumar³. ¹Laboratories, Barnes-Jewish Hospital, St. Louis, MO, USA; ²Medicine, Washington University School of Medicine, St. Louis, MO, USA; ³Surgery, Washington University School of Medicine, St. Louis, MO, USA.

90-P
ROLE OF XM-One IN RENAL TRANSPLANTATION.

Donna L. Phelan¹, Lauren Wetter¹, T. Mohanakumar², Christina Klein³. ¹Laboratories, Barnes-Jewish Hospital, St. Louis, MO, USA; ²Surgery, Washington University School of Medicine, St. Louis, MO, USA; ³Medicine, Washington University School of Medicine, St. Louis, MO, USA.

91-P
IS A 10/10 REALLY PERFECT?

Siva Kanangat¹, Michele H. Prod¹, Maria Oppermann¹, Sylvia C. Piggott¹, Ina Kurbegovic-Skaljic¹, Stephen C. Jensik¹, Andres Jaramillo². ¹Pathology-HLA, Rush University Medical Center, Chicago, IL, USA; ²Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA.
Abstracts

92-P
HUMORAL ALLOIMMUNITY IN BOWEL/MULTIVISCERAL TRANSPLANTATION – HIGH INCIDENCE OF SENSITIZATION AND THE SIGNIFICANCE OF A RISING DONOR SPECIFIC ANTIBODY TITER IN THE DIAGNOSIS AND PROGNOSIS OF INTESTINAL REJECTION.
Phillip Ruiz¹, Hsin-Lin Tsai¹, Ignacio Gonzalez-Pinto¹, Panagiotis Tryphonopoulos¹, Jennifer Garcia², Deborah Cova¹, Seigo Nishida¹, Akin Tekin¹, Debbie Weppler¹, Andreas Tzakis¹. ¹Surgery, University of Miami, Miami, FL, USA; ²Pediatrics, University of Miami, Miami, FL, USA.

93-P
ANALYSIS OF HLA ANTIBODY TITER AND C1q BINDING CAPABILITY IN PRIVIGEN AND CARIMUNE IVIG PREPARATIONS.
Jon Lomago, Suzan Russell-Vaskov, John Lunz, Joan Martell, Betty Hunter, Donald Foster, Adriana Zeevi. Pathology, UPMC, Pittsburgh, PA, USA.

94-P
C1q POSITIVE ANTIBODIES IN PATIENTS WITH DONOR SPECIFIC HLA ANTIBODIES AND POST TRANSPLANT REJECTION.
Jerome G. Saltarrelli¹, Jacqueline A. Lappin¹, Stephen M. Katz¹, Karoly Varga¹, Charles T. Van Buren¹, Laszlo A. Bihari¹, Daniel J. Cook¹, Dolly Tyan², Ronald H. Kerman¹, Ge Chen¹. ¹Surgery-Organ Transplantation, University of Texas Medical School at Houston, Houston, TX, USA; ²Stanford University School of Medicine, Palo Alto, CA, USA.

95-P
INCREASED RISK FOR BRONCHIOLITIS OBLITERANS IN LUNG TRANSPLANT RECIPIENTS WHO DEVELOP POST TRANSPLANT DONOR SPECIFIC HLA ANTIBODIES.
Kathy Spichty¹, Matthew Morrell³, Joseph Piliewski³, Diana Zaldonis², Maria Crespo³, Yoshiya Toyoda², Adriana Zeevi¹. ¹Pathology, University of Pittsburgh, Pittsburgh, PA, USA; ²Cardiothoracic Surgery, UPMC, Pittsburgh, PA, USA; ³Pulmonary Medicine, UPMC, Pittsburgh, PA, USA.

96-P
RELATIVE RATIO, POSITIVE CONTROL BEAD MFI, SELF-MOLECULES MFI: A COMPARISON STUDY OF CUT OFF CALCULATION METHODS AND THEIR CORRELATION TO THE 500 MFI VALUE.
Carolina Kneib, Liliane Machado Nascimento, Roberta Amorim Bogocheviski, Bruna Paladino Vieira, Priscila Siqueira Rodrigues, Renata von Glehn Ponsirenas, Cristina de Queiroz Carrascalas von Glehn, Michelle Fernanda Susin. Transplant Immunology Laboratory, Pontifical Catholic University of Parana - PUCPR, Curitiba, Parana, Brazil.
Abstracts

97-P
DSA VS. NDSA REACTIONS AGAINST DISULFIDE BOND-REDUCED HLA CLASS II DQ ANTIGENS.
Michiko Taniguchi1, Paul Terasaki2, Judy Hopfield1, Nubia Banuelos1, Po-Chang Lee3. 1Research II, One Lambda, Inc., Los Angeles, CA, USA; 2Terasaki Foundation Laboratory, Terasaki Foundation Laboratory, Los Angeles, CA, USA; 3National Cheng Kung University Hospital, National Cheng Kung University Hospital, Tainan, Taiwan.

98-P
ALLORESPONSE AFTER SKIN TRANSPLANTATION: ACTIVATION THROUGH THE SEMI-DIRECT PATHWAY?
Georges Tocco1, Cavit D. Kant1, Pilhan Kim2, Charles Lin2, Seok-Hyun Yun2, Gilles Benichou1. 1Surgery/Transplant Center, MGH, Boston, MA, USA; 2Wellman Center for Photomedicine, MGH, Boston, MA, USA.

99-P
PREFORMED AND DE NOVO HLA DQα ANTIBODIES CAUSE AMR IN RENAL ALLOGRAFTS.
Khalid Al Meshari1, Abeer Pall1, Hazem Elgamal1, Fadi Alzayer2, Moheeb Al Awwami2. 1Renal Transplant, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2Pathology & Laboratory Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.

100-P
ANTI-HLA-C DONOR SPECIFIC ANTIBODY ASSOCIATED WITH ACUTE CELL-MEDIATED RENAL TRANSPLANT REJECTION.
Fleur M. Aung1, Kevin M. Burns2, Geoffrey A. Land2. 1Laboratory Medicine/HLA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Pathology/Laboratory Medicine/HLA, The Methodist Hospital, Houston, TX, USA.

101-P
PRESENCE OF ALLOANTIBODY AND ABO ANTIBODY IN IVIG PREPARATIONS.
Benita K. Book1, Nancy K. Higgins3, Jeanne M. Chen3, Andrew J. Lobashevsky3, Ahmad M. Mujtaba2, Tim E. Taber1. 1Surgery, Indiana University School of Med, Indianapolis, IN, USA; 2Nephrology, Indiana University School of Med, Indianapolis, IN, USA; 3Transplant Institute, IU Health, Indianapolis, IN, USA.

102-P
Syk AS A TARGET IN TOLERANCE INDUCTION.
Raphael Clynes. Pathology, Columbia University, New York, USA.
Abstracts

103-P
C1q- BINDING ALLOANTIBODIES IN SENSITIZED PATIENTS VARY IN PROPORTION OF POSITIVITY AND MAY BE ASSOCIATED WITH POST-TRANSPLANT GRAFT REJECTION: INITIAL OBSERVATIONS.
Deborah Y. Cova, Carmen Gomez, Gaetano Ciancio, Linda Chen, David Roth, Warren Kupin, J. Sageshima, G. Guerra, G.W. Burke III, Phillip Ruiz. Department of Surgery /Transplant Laboratory, University of Miami, Miami, FL, USA.

104-P
SEMAPHORIN 5A ACTIVATES NK AND T CELL RESPONSES IN AN ANTIGEN-INDEPENDENT MANNER.
Christiane Gras, Britta Eiz-Vesper, Stephan Immenschuh, Rainer Blasczyk, Constanca Figueiredo. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

105-P
SHORT-TERM RENAL TRANSPLANT OUTCOME IN RECIPIENTS WITH A POSITIVE PRE-TRANSPLANT CROSSMATCH: THE OPTN DATA.
Indira Guleria, Isabelle G. Wood, Edgar L. Milford. Tissue Typing Laboratory, Brigham and Women’s Hospital, Boston, MA, USA.

106-P
CLINICAL SIGNIFICANCE OF DYNAMIC MONITORING OF ANTI-HLA AND ANTI-MICA ANTIBODIES AFTER RENAL TRANSPLANTATION AND SPECIFIC IMMUNOADSORPTION OF ANTI-HLA DR ANTIBODIES.
Quan Jian Hou. Urology Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

107-P
CHANGES IN CONCENTRATION OF DONOR-SPECIFIC ANTIBODIES TO HLA PREDICT CLINICAL RESPONSE TO PLASMAPHERESIS FOR ANTIBODY-MEDIATED HEART AND LUNG TRANSPLANT REJECTION.
Ronald Jackups, Jr, Gerald Morris. Pathology, Washington University, St. Louis, MO, USA.

108-P
C4d+ ANTIBODY MEDIATED REJECTION IN ABSENCE OF COMPLEMENT FIXING DONOR SPECIFIC ANTIBODY FOR A HEART TRANSPLANT PATIENT.
Chih-Hung Lai1, Robin Masukawa1, Dianne V. Paredes1, Geraldine Ong1, Qi Wang1, Mehrnoush Naim1, Kai Cao1, Jon A. Kobashigawa2, Nancy L. Reinsmoen1. 1HLA Lab, Cedars-Sinai Health System, Los Angeles, USA; 2Heart Transplant Program, Cedars-Sinai Health System, Los Angeles, USA.
Abstracts

109-P
AN APPROACH TO MONITORING DESENSITIZATION IN A PATIENT WITH A NATURALLY-OCcurring INTERFERING SUBSTANCE.
David Maurer¹, Harriet Noreen¹, Peggy Krefting¹, Daniel Borja-Cacho², Gerardo Tamayo², Ty B. Dunn². ¹Lab Med. & Pathology, University of Minnesota Medical Center, Minneapolis, USA; ²Surgery, University of Minnesota Medical Center, Minneapolis, MN, USA.

110-P
CLINICAL SIGNIFICANCE OF ALLOANTIBODIES DETECTED BY CELL BASED AND SOLID PHASE ASSAYS IN LIVE RELATED DONOR RENAL TRANSPLANTS.
Narinder K. Mehra¹, Jamshaid A. Siddiqui¹, Gurvinder Kaur¹, Dipankar K. Bhowmik², Sandeep Guleria², Sanjay K. Agarwal³. ¹Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India; ²Nephrology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India; ³Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India.

111-P
UNCLEAR BENEFIT OF BORTEZOMID IN THE TREATMENT OF ACUTE HUMORAL REJECTION.
Maria B. Rodríguez¹, Karin Padrós¹, Olga L. Vanco¹, Javier C. Walther², Domingo H. Casadei². ¹Histocompatibility, PRICAI-Favaloro Foundation, Ciudad Autónoma de Buenos Aires, Argentina; ²Kidney Transplant, Instituto de Nefrología Nephrology, Ciudad Autónoma de Buenos Aires, Argentina.

112-P
CLINICAL RELEVANCE OF CYTOKINE GENE POLYMORPHISM ON POST TRANSPLANT RENAL ALLOGRAFT SURVIVAL.
Jamshaid A. Siddiqui¹, Gurvinder Kaur¹, Dipankar M. Bhowmik², Sandeep Guleria², Sanjay K. Agarwal³, Narinder K. Mehra¹. ¹Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India; ²Nephrology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India; ³Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India.

113-P
ANTIBODY-MEDIATED REJECTION IN HEART TRANSPLANT RECIPIENTS: LONG TERM FOLLOW UP OF PATIENTS WITH HIGH LEVELS OF DONOR-DIRECTED ANTI-DQ ANTIBODIES.
Erin H. Ticehurst¹, Maria R. Molina², Jane Kearns³, Lee Goldberg², Donald Tsai², Joyce W. Wald², Malek Kamoun³. ¹Pharmacy, University of Pennsylvania, Philadelphia, PA, USA; ²Medicine, University of Pennsylvania, Philadelphia, PA, USA; ³Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstracts

114-P
POST-TRANSPLANT DONOR SPECIFIC ANTIBODY MONITORING IS ENHANCED BY DILUTION ANALYSIS AND C1Q BINDING ASSESSMENT VIA SINGLE ANTIGEN REAGENTS.
R. Carlin Walsh\(^1\), Hal Gibson\(^3\), Owen Buenaventura\(^1\), Anthony Portale\(^2\), Lee Ann Baxter-Lowe\(^1\).
\(^1\)Immunogenetics & Transplantation Laboratory, University of California, San Francisco, CA, USA; \(^2\)Pediatrics, Nephrology, University of California, San Francisco, CA, USA; \(^3\)One Lambda, Inc, Canoga Park, CA.

115-P
CLINICAL EFFICACY OF SIROLIMUS-BASED QUADRUPLE THERAPY IN THE TREATMENT OF ACUTE REJECTION AT THE EARLY STAGE AFTER RENAL TRANSPLANTATION.
Weigang Wang\(^1\), Yuantao Wang\(^1\), Honglan Zhou\(^1\), Ping Li\(^2\), Gang Wang\(^1\), Yaowen Fu\(^1\).
\(^1\)Urinary Diseases Diagnosis & Treatment Center, First Bethune Hospital of Jilin University, Changchun, China; \(^2\)Department of Rheumatology, China-Japan Union Hospital of Jilin University, Changchun, China.

116-P
ASSOCIATION OF IL-10 PROMOTER POLYMORPHISMS WITH PROSTATE CANCER RISK IN AFRICAN-AMERICANS.
Muneer M. Abbas\(^1,2\), Tshela M. Mason\(^1\), Luicel Ricks-Santi\(^1,3\), George E. Bonney\(^1,4\), Victor Apprey\(^1,4\), Rick Kittles\(^5\), Chiledum Ahaghotu\(^6\), Georgina M. Dunston\(^1,2\).
\(^1\)The National Human Genome Center, Howard University, Washington, DC, USA; \(^2\)Microbiology, Howard University, Washington, DC, USA; \(^3\)Cancer Center, Howard University, Washington, DC, USA; \(^4\)Community Health and Family Medicine, Howard University, Washington, DC, USA; \(^5\)The Institute of Human Genetics, University of Illinois at Chicago, Chicago, IL, USA; \(^6\)Urology, Howard University Hospital, Washington, DC, USA.

117-P
PREDICTING THE PRESENCE OF HLA-C*02:10 BASED ON ALLELES AT HLA-A AND -B LOCI AND RACE.
Maria Zlobinsky\(^1\), John Barnard\(^2\), Garnett Smith\(^3\), Aiwen Zhang\(^4\), Dawn Thomas\(^4\), Paul Kawczak\(^4\), Susannah Brown\(^4\), Chad Eliason\(^4\), Medhat Askar\(^4\).
\(^1\)Colleges of Medicine and Pharmacy, Northeastern Ohio Universities, Rootstown, USA; \(^2\)Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, USA; \(^3\)Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, USA; \(^4\)Allogen Laboratories, Cleveland Clinic, Cleveland, USA.
Abstracts

**118-P**
**Allele Frequency Assessment of 18 Minor Histocompatibility Antigens (mHags) in African Americans.**
Gina R. Bakker, Marcela R. Uribe, Sharon D. Adams, Willy A. Flegel. Dept. of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA.

**119-P**
**A Novel HLA-DRB1 Allele Identified in a Brazilian Volunteer Bone Marrow Donor.**
Sibelle B. Mattar, Pryscilla F. Wowk, Maria da Graça Bicalho. Departamento de Genética, Laboratório de Imunogenética e Histocompatibilidade da Universidade Federal do Paraná, Curitiba, Paraná, Brazil.

**120-P**
**A Potential Novel HLA-DRB1*03 Allele Identified by Sequence-Based Typing in a Potential Chinese HSCT Donor.**
Xiangmin Nie1,2, Chuanfu Zhu1, Yonghong Song1, Yi Zhang1, Yunlong Zhuang1, Yan Liu1, Angeli-ca DeOliveira2, Bobbie Holeman2, Candace Young2, Gansuvd Balgansuren2, Dong-Feng Chen2. 1HLA Laboratory, Blood Center of Shandong Province, Jinan, Shandong Province, China; 2Clinical Transplantation Immunology Laboratory, Duke University Medical Center, Durham, NC, USA.

**121-P**
**A Potential Novel HLA-B*35 Allele Identified by Sequence-Based Typing in a Potential Chinese HSCT Donor.**
Xiangmin Nie1,2, Chuanfu Zhu1, Yonghong Song1, Yi Zhang1, Yunlong Zhuang1, Yan Liu1, Angeli-ca DeOliveira2, Bobbie Holeman2, Candace Young2, Gansuvd Balgansuren2, Dong-Feng Chen2. 1HLA Laboratory, Blood Center of Shandong Province, Jinan, Shandong Province, China; 2Clinical Transplantation Immunology Laboratory, Duke University Medical Center, Durham, NC, USA.

**122-P**
**Role of Haptoglobin and Its Polymorphism in Bronchial Asthma.**
Margarida M.T.C. Cortez e Castro1, Joana Ferreira2, Manuel Bicho2, Cláudia Marinho2. 1Immu-noAllergy, CHLN-HSM, Lisbon, Portugal; 2Genetic Department, Lisbon Medical School, Lisbon, Portugal.

**123-P**
**The IPD-MHC NHP Database: New Nomenclature for the Non-Human Primate MHC Alleles.**
Natasja G. de Groot1, Nel Otting1, James Robinson2, Steven G.E. Marsh2, Ronald E. Bontrop1. 1Comparative Genetics and Refinement, Biomedical Primate Research Centre, Rijswijk, Netherlands; 2Royal Free Hospital, Anthony Nolan Research Institute, London, United Kingdom.
Abstracts

124-P
HLA-E IN THE BRAZILIAN POPULATION: DIVERSITY OF CODING REGION AND NEW VARIATION SITES.
Luciana C. Veiga-Castelli1, Erick C. Castelli2, Celso T. Mendes, Jr3, Wilson A. Silva, Jr4, Marie-Claude Faucher5, Karine Beauchemin5, Michel Roger5, Phillipe Moreau6, Eduardo A. Donadi1.
1Divisão de Imunologia Clínica, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil; 2Laboratório de Genética Molecular e Citogenética, Departamento de Biologia Geral, Instituto de Ciências Biológicas, University of Goias, Goiânia, Goias, Brazil; 3Departamento de Química, Facultade de Filosofia, Ciências e Letras de Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil; 4Departamento de Genética, Faculdade de Medicina de Ribeirão Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil; 5Département de Microbiologie et Immunologie, Centre Hospitalier de L’Université de Montréal, Université de Montréal, Montreal, QC, Canada; 6Commissariat à l’Energie Atomique/DSV/12BM/Service de Recherches en Hémato-Immunologie, IUH, Hôpital Saint-Louis, Paris, France.

125-P
DIFFERENTIAL REGULATION OF THE EFFECTOR CELL FUNCTION BY SEMAPHORIN 7A VARIANTS EXPLAIN THEIR DISEASE ASSOCIATION.
Constanca Figueiredo, Christiane Gras, Britta Eiz-Vesper, Axel Seltsam, Rainer Blasczyk. Hannover Medical School, Institute for Transfusion Medicine, Hannover, Germany.

126-P
A NEW C*03:02 VARIANT THAT ESCAPED LABType SSO DETECTION.
Justine L. Gaspari1, Lindley C. Blair2, Jenn Tyler1, Heather A. Casey1, Ronald E. Domen1, Hiroko Shike1. 1Pathology, HLA laboratory, Penn State Hershey Medical Center, Hershey, PA, USA; 2Research, One Lambda, Inc., Canoga Park, CA, USA.

127-P
THE KIR AB HAPLOTYPE IS ASSOCIATED WITH SUSCEPTIBILITY IN VOGT-KOYANAGI-HARADA (VKH) DISEASE IN MEXICANS.
C. Alaez1, H. Flores1, L.E. Concha2, L. Arellanes2, D. Senitzer3, C. Gorodezky1. 1Dept. of Immunology & Immunogenetics, InDRE, Secretary of Health, Mexico City, DF, Mexico; 2Asociación para Evitar la Ceguera en México, I A.P. Hospital “Dr. Luis Sánchez Bulnes, Inflammatory Eye Disease Clinic, Mexico City, DF, Mexico; 3HLA laboratory, City of Hope National Medical Center, Duarte, CA, USA.

128-P
HAPLOTYPE FREQUENCY ESTIMATION INCORPORATING DRB3/4/5 LOCI.
Loren Gragert, Martin Maiers. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.
Abstracts

129-P
CONTRIBUTION TO INTERLEUKIN GENE POLIMORPHISMS STUDY IN REUMATHOID ARTHRITIS.
Alberto J. Leon1, Victoriano J. Leon2, Ruth Lopez Gonzalez3, Carlos Montilla Morales4. 1Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 2Servicio Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain; 3Servicio de Reumatologia, Hospital Universitario de Salamanca, Salamanca, Spain.

130-P
ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISM IN THE INF-γ, IL1-β AND TGF-β GENE PROMOTER WITH POLYOMA VIRUS BK VIRUS REACTIVATION AFTER KIDNEY TRANSPLANTATION.
Abdelhamid Liacini1, Faisal Masood Khan2, Lee Anne Tibbles3, Serdar Yilmaz3, Noureddine Berka1. 1Pathology & Laboratory Medicine, Calgary Laboratory Services, Calgary, AB, Canada; 2Pathology & Laboratory Medicine and Paediatrics, University of Calgary/Calgary Laboratory Services, Calgary, AB, Canada; 3Medicine, Division of Transplantation, University of Calgary, Calgary, AB, Canada.

131-P
HLA CLASS I ALLELIC FREQUENCY DISTRIBUTION IN THE LEBANESE POPULATION: THE LARGEST REPORT FROM LEBANON IN PREPARATION FOR A NATIONAL REGISTRY.
Sara Khansa, Rouba Hoteit, Layal Greige, Hussein Halas, Rabab Abdel Khalek, Fatmeh Abbas, Dina Shammas, Rami Mahfouz. Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

132-P
HLA CLASS II ALLELIC FREQUENCY DISTRIBUTION IN THE LEBANESE POPULATION: THE LARGEST REPORT FROM LEBANON IN PREPARATION FOR A NATIONAL REGISTRY.
Hussein Halas, Sara Khansa, Rouba Hoteit, Layal Greige, Rabab Abdel Khalek, Fatmeh Abbas, Dina Shammas, Rami Mahfouz. Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

133-P
TYPE 1 DIABETES ASSOCIATED HLA-DR3 HAPLOTYPES ARE UNIQUE IN THE INDIAN POPULATION.
Narinder K. Mehra, Neeraj Kumar, Gurvinder Kaur. Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Delhi, India.

134-P
GENOTYPE OF KIR AND ITS RELATIONSHIP WITH GASTRIC DISEASES.
Martha Perez-Rodriguez1, Margarita Camorlinga-Ponce2, Javier Torres2. 1Unidad de Investigación Médica en Inmunología, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico; 2Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico.
Abstracts

135-P
GETTING OUT OF THE GROOVE, PART 2: PATTERNS OF SINGLE NUCLEOTIDE POLYMORPHISMS WITHIN CLASS II EXON 3 SEQUENCES.
Lois E. Regen1, Shalini E. Pereira1,2,3. 1CIL, Seattle Cancer Care Alliance, Seattle, WA, USA; 2Clinical Research Division, FHCRC, Seattle, WA, USA; 3Lab Medicine, University of Washington, Seattle, WA, USA.

136-P
EXTENDED HLA HAPLOTYPE SCREENING OF FAMILIES USING SHORT TANDEM REPEATS.
Jennifer Schiller, Monaal Barakat, Tracy Fisher, Susan Gaba, Tere Hasse, Thomas Ellis. Histocompatibility and Immunogenetics, BloodCenter of Wisconsin, Milwaukee, WI, USA.

137-P
INHIBITORY KIRs AND THEIR HLA LIGANDS IN RUSSIAN POPULATION FROM NORTHWEST REGION.
Julia V. Sokolova, Ludmila N. Bubnova, Irina E. Pavlova. Laboratory of Immunohematology, Russian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation.

138-P
KILLER Ig-LIKE RECEPTOR (KIR) GENE POLYMORPHISMS AND CROHN DISEASE IN BRAZILIAN POPULATION.
Priscila Saamara Mazini1, Andressa Alves Gonçalves1, Jeane Eliete Visentainer1, Maria Luiza Petzl-Erler2, Luiza Tamie Tsuneto1. 1Ciências Básicas da Saúde, State University of Maringá, Maringá, Paraná, Brazil; 2Genetic, Federal University of Paraná, Curitiba, Paraná, Brazil.

139-P
THE INCIDENCE OF MICA ALLELE MISMATCHES AMONG HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS AND DONORS SHARING SIMILAR HLA GENOTYPES AT LOCI A*, C*, B*, DRB1*, AND DQB1*.
Dawn Thomas, Aiwen Zhang, Raymond Jurcago, Paul Kawczak, Heather Eilrich, Kevin Minotti, Medhat Askar. Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA.

140-P
DONOR KIR2DS2 GENE IS ASSOCIATED WITH AN INCREASED RATE OF TRM AFTER UNRELATED HEMATOPOIETIC SCT IN THE CHINESE POPULATION.
Xiaojing Bao, Jun He. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Abstracts

141-P
HLA-DP: ITS RELEVANCE FOR BROADLY SENSITIZED HEMATOPOIETIC STEM CELL RECIPIENTS.
Suraya A. Berger, Nancy D. Rossiter, Renato M. Vega, Julie A. Houp, Mary S. Leffell. Medicine, Johns Hopkins University, Baltimore, MD, USA.

142-P
ALLOGENICITY AND IMMUNOGENICITY: CHALLENGES IN CARDIAC STEM CELL REGENERATIVE THERAPY.

143-P
A GUIDELINE FOR OPTIMAL MINIMUM TOTAL NUCLEATED CELL COUNT FOR CORD BLOOD UNIT BANKING.
Loren Gragert, Martin Maiers, Michael Boo, Dennis Confer. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

144-P
A COST-BENEFIT ANALYSIS FOR RECRUITMENT OF ADULT DONORS VS CORD BLOOD UNITS IN THE BE THE MATCH REGISTRY.
Loren Gragert, Martin Maiers, Michael Boo, Dennis Confer. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

145-P
IMPACT OF HLA HIGH-RESOLUTION DONOR-RECIPIENT MISMATCHING ON UNRELATED DONOR HSCT FROM CMDP.
Jun He. HLA Lab, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China.

146-P
HIGH-THROUGHPUT HLA-TYPING VIA “TOUCH REHYDRATION” OF DRIED BLOOD ON GUTHRIE CARDS.
Gina Lopez Padilla, Michael Brown, Kevin O’Brien, Mike Hogan. Research & Development, gmsbiotech, Tucson, AZ, USA.

147-P
PLATELET DIFFERENTIATION FROM CD34+ PROGENITOR CELLS IS INHIBITED BY SEMAPHORIN 7A.
Yarúa Jaimes, Christiane Gras, Stephan Immenschuh, Rainer Blaszczyk, Constanca Figueiredo. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.
Abstracts

148-P
HLA-E POLYMORPHISMS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Daniel Fürst1, Jovana Bindja1, Renate Arnold2, Wolfgang Herr3, Schwerdtfeger Rainer4, Carl-Heinz Mueller5, Kirsten Recker1, Schrezenmeier Hubert1, Mytilineos Joannis1. 1Transplantation Immunology, Institute for Clinical Transfusion Medicine and Immunogenetics, Ulm, Germany; 2Hematology/Oncology Department, Charité Campus Virchow Berlin, Berlin, Germany; 3Hematology/Oncology Department, University Medical Center of Johannes Gutenberg University, Mainz, Germany; 4Hematology/Oncology Department, Stiftung DKD GmbH Wiesbaden, Wiesbaden, Germany; ZKRD - Zentrales Knochenmarkspender-Register für Deutschland, German National Bone Marrow Donor Registry, Ulm, Germany.

149-P
HISTORICAL BE THE MATCH REGISTRY HLA MATCH RATES FOR ADULT DONOR AND CORD BLOOD UNITS (CBU) FROM THE INCEPTION OF THE REGISTRY.
Martin Maiers, Dennis Confer, Loren Gragert, Eric Williams, John Freeman. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

150-P
HOW RELIABLE ARE MANUFACTURERS’ PREDICTED HIT PATTERNS THAT ARE BASED ON SEQUENCE HOMOLOGY OF RELATED ANTIGENS?

151-P
IMMUNE PROFILING WITH HIGH-THROUGHPUT SEQUENCING.
Harlan Robins, Christopher Carlson. Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

152-P
HLA-DPA1 MISMATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND IMPAIRED OVERALL SURVIVAL – A SINGLE CENTRE EXPERIENCE.
Marie Schaffer1, Mats Remberger1,2, Olle Ringdén1,2, Richard Olsson1,2. 1Division of Clinical Immunology F79, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden; 2CAST, Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden.

153-P
DSA IN RECIPIENTS OF DOUBLE CBT – INFLUENCE ON ENGRAFTMENT OF SPECIFIC UNITS?
Diane Zebert1, Ivy B. Rifkin1, Filippo Milano1, Colleen Delaney1,4, Shalini E. Pereira1,2. 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Department of Lab Medicine, University of Washington, Seattle, WA, USA; 3Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; 4Department of Pediatrics, University of Washington, Seattle, WA, USA.
Abstracts

154-P
LinkSeq™ AND SureTyper™ – A RAPID REAL-TIME PCR SYSTEM FOR HLA TYPING.
Zachary C. Antovich1, Roland Russnak1, Ngoc Ly1, Kai Quinto1, Matthew Frome1, Eric Mitchell1, F. Carl Grumet1. 1Diagnostics, Linkage Biosciences Inc., San Francisco, CA, USA; 2Pathology, Stanford University, Stanford, CA, USA.

155-P
POCKETCHECK: A COMPREHENSIVE CONTACT CALCULATION FOR DISTINCT PEPTIDE-HLA STRUCTURES.
Trevor Huyton, Nektarios Ladas, Rainer Blasczyk, Christina Bade-Doeding. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

156-P
SPECIFIC REMOVAL OF HLA CLASS I DIRECTED ANTIBODIES FROM HUMAN SERA.
David Lowe1,2, Curtis McMurtrey3, Daniel Zehnder2,4, Steven Cate3, Robert Higgins4, Rico Buchli5, Daniel Mitchell5, Rodney VanGundy6, William Hildebrand3,5, David Briggs1. 1NHS Blood & Transplant, NHS Blood & Transplant, Birmingham, United Kingdom; 2Clinical Sciences Research Institute, University of Warwick, Coventry, United Kingdom; 3Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 4Renal Department, University Hospital Coventry and Warwickshire, Coventry, United Kingdom; 5Pure Protein LLC, Pure Protein LLC, Oklahoma City, OK, USA.

157-P
THE ANTIBODY RESPONSE TO AN HLA MISMATCH: A MODEL FOR NON-SELF-SELF DISCRIMINATION IN RELATION TO HLA EPITOPE IMMUNOGENICITY.
Rene J. Duquesnoy. Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

158-P
COMPLETE CHARACTERIZATION OF 12 MHC GENES FOR MULTIPLE SAMPLES BY NEXT-GENERATION SEQUENCING.
Deborah Ferriola1, Curt Lind1, Steven Heron1, Anh Huynh1, Larissa Slavich1, Ariella Sasson2, Xiaowu Gai2, Dimitri Monos1,3. 1Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, USA; 2Bioinformatics Core Facility, The Children’s Hospital of Philadelphia, Philadelphia, USA; 3Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA.
Abstracts

159-P
HISTOCOMPATIBILITY TESTING WITH DNA ISOLATED FROM BUCCAL SWABS USING THE Maxwell® 16 BUCCAL SWAB LEV DNA PURIFICATION KIT.
Rebecca Gorshe¹, Jennifer Schiller², Thomas Ellis², Tracy Fisher², Trista Schagat¹. ¹Scientific Applications Support, Promega Corporation, Madison, WI, USA; ²Histocompatibility and Immunogenetics, Blood Center of Wisconsin, Milwaukee, WI, USA.

160-P
COMPLETE GENOMIC CHARACTERIZATION OF 37 COMMON AND WELL-Documented HLA CLASS I ALLELES USING NEXT-GENERATION SEQUENCING TECHNOLOGY.
Curt Lind¹, Deborah Ferriola¹, Laura McLaughlin¹, Ariella Sasson², Xiaowu Gai², Dimitri Monos¹,³. ¹Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; ²Bioinformatics Core Facility, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; ³Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

161-P
SPECIFIC REMOVAL OF ANTIBODIES TO HLA-DRB1 FROM PATIENT SERA.
Curtis P. McMurtrey¹, David Lowe³,⁴, Andy Dutty¹, Steven Cate¹, Sean Osborn¹, Aleksandar Moj-silovic¹, Robert Higgins³, Rodney VanGundy², Rico Buchli², David Briggs³, William Hildebrand¹,². ¹Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; ²Pure Protein LLC, Oklahoma City, OK, USA; ³NHS Blood & Transplant, Birmingham, United Kingdom; ⁴Clinical Sciences Research Institute, University of Warwick, Coventry, United Kingdom; ⁵Renal Department, University Hospital Coventry and Warwickshire, Oklahoma City, OK, USA.

162-P
SBTengine®, THE ULTIMATE SOLUTION FOR HIGH RESOLUTION HLA TYPING.

163-P
HIGH RESOLUTION HLA TYPING FOR COMPANION DIAGNOSTICS USING THE NEXT GENERATION DNA SEQUENCING STRATEGY: PYROSEQUENCING.
Maarten Penning¹, Albert Wijngaard¹, Jeroen Adema¹, Daan Acohen¹, Ron Opstelten², Wietse Mulder¹, Erik Rozemuller¹. ¹R&D, Genome Diagnostics BV, Utrecht, Netherlands; ²Corporate Business Development, Qiagen, Hilden, Germany.

164-P
NEW ROBUST HLA-B*27 DETECTION ASSAY BASED ON REAL-TIME PCR.
Abstracts

165-P
ALLELE FREQUENCIES OF HUMAN NEUTROPHIL ANTIGEN-3 (HNA-3) IN AN AFRICAN AMERICAN POPULATION.
Michael J. Huvard, Pirmin Schmid, Willy A. Flegel. Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA.

166-P
WANT A GOOD READ? NEXT-GENERATION HLA SEQUENCING USING THE ROCHE 454 GS FLX PLATFORM FOR FIVE NIH PROJECTS.
Elizabeth Trachtenberg1,2, Martha Ladner1, Kazu Osoegawa3, Franziska Cohen2, Sherry Hawbeker2, Fernanda Ribas Zacarias2, David Noonan2, Shana White3, Kellie Graham1, John Agraz1, Kathy Mohr1, Margaret Vinson1, Damian Goodridge2,3. 1Center for Applied Genomics, Children’s Hospital & Research Center Oakland (CHRCO), Oakland, CA, USA; 2Center for Genetics, Children’s Hospital Oakland Research Center (CHORI), Oakland, CA, USA; 3Conexio Genomics Pty, LTD, Freemantle, Western Australia, Australia.

167-P
CLINICALLY RELEVANT ANTIBODIES ARE DETECTED BY C1q AND INDEPENDENT OF IgG MFI ON THE LUMINEX SINGLE ANTIGEN BEADS.
Ge Chen, Flavia Sequeira, Dolly Tyan. Pathology, Stanford University, Palo Alto, CA, USA.

168-P
MOLECULAR TYPING METHODS FOR THE NON-CLASSICAL HLA-E GENE.
Christina E.M Voorter, Nina Lauterbach, Timo Olieslagers, Marcel G.J. Tilanus. Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Centre, Maastricht, Netherlands.

169-P
EXCLUDING ALLELES BY POPULATION FREQUENCY: IS THIS A RISKY BUSINESS?
Nebila Abdulwahab, Patrick Adams, Adam Schoen, Nicholas Dipaola. Clinical Histocompatibility Laboratory, The Ohio State University Medical Center, Columbus, OH, USA.

170-P
A SINGLE CENTER EXPERIENCE IN TRANSITIONING HIGH RESOLUTION TYPING FROM SSP TO SBT.
Adam Schoen, Nebila Abdulwahab, Nicholas Dipaola. Clinical Histocompatibility Laboratory, The Ohio State University Medical Center, Columbus, OH, USA.
Abstracts

**171-P**
SIGNIFICANCE OF PRE AND POST TRANSPLANT HLA ANTIBODY (HLA Ab) IN A HISPANIC RENAL TRANSPLANT POPULATION.
Carlos R. Alvarez-Allende1, Mariselle Torres2, Blanca Camacho2, Sally de Echegaray2, Eduardo Santiago-Delpín1. 1Hospital Auxilio Mutuo, Puerto Rico Renal Transplant Program, San Juan, PR, Puerto Rico; 2Hospital Auxilio Mutuo, Immunogenetics Laboratory, San Juan, PR, Puerto Rico; 3Surgery, University of Puerto Rico Medical School, San Juan, PR, Puerto Rico.

**172-P**
DQB1*03:19 ALLELE DISTRIBUTION AND RELATIVE HAPLOTYP FREQUENCY AMONG CAUCASIANS, AFRICAN AMERICANS AND HISPANICS.
Paul Kawczak1, Garnett Smith2, Amy Nowacki3, John Barnard1, Maria Zlobinsky4, Dawn Thomas1, Isam Zaim1, Medhat Askar1. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA; 2Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA; 3Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA; 4Colleges of Medicine and Pharmacy, Northeastern Ohio Universities, Rootstown, OH, USA.

**173-P**
HLA-DQA1 LOCUS SEQUENCING ASSAY.
Dina Berchanskiy, Tina Agostini, James Meegan, David Dinauer. RnD, Life Technologies, Brown Deer, WI, USA.

**174-P**
NASAL CARRIAGE OF STAPHYLOCOCCUS AUREUS IN HEMODIALYSIS AND TRANSPLANTED PATIENTS AND ITS ASSOCIATION WITH HLA MOLECULES.
Luciana Borges Giarola1, Rosiane Ribeiro dos Santos2, João Bedendo3, Waldir Veríssimo da Silva Júnior4, Sueli Donizete Borelli5. 1Nursing, State University of Maringa, Maringa, Parana, Brazil; 2Program of Healthy Science, State University of Maringa, Maringa, Parana, Brazil; 3Nursing, State University of Maringa, Maringa, Parana, Brazil; 4Statistic, State University of Maringa, Maringa, Parana, Brazil; 5Basic Science of Healthy, State University of Maringa, Maringa, Parana, Brazil.

**175-P**
THE POLYMORPHISM OF THE HLA SYSTEM.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

**176-P**
MEASURING HLA TYPING RESOLUTION.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

**177-P**
OPEN COLLABORATION IN IMMUNOGENETICS AND HISTOCOMPATIBILITY.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.
Abstracts

**178-P**
THE GEOMETRY OF HLA TYPING REACTIVITY PATTERNS: DOING AWAY WITH FALSE-POSITIVE AND FALSE-NEGATIVE REACTIONS.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

**179-P**
THE INCIDENCE OF RARE AND NEW HLA ALLELES.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

**180-P**
PROBLEMS AND DIFFICULTIES IN HLA TYPING.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

**181-P**
WHICH HLA TYPING AMBIGUITIES SHOULD BE RESOLVED.
Pedro Cano. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

**182-P**
SEQUENCING WITH INCOMPLETE REFERENCE SEQUENCE IN HLA TYPING.
Pedro Cano. Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

**183-P**
EVOLVING PRACTICE IN HLA TYPING OF UMBILICAL CORD BLOOD.
Lesa Foley², Carly Carozza¹, Katherine Wanenchak¹, Eric Pimpinella¹, Monica Rocheford², Susan Hsu¹. ¹HLA/Molecular Genetics, ARC Penn-Jersey Region, Philadelphia, PA, USA; ²Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

**184-P**
CORRELATIONS OF COMPLEX DISEASE-ASSOCIATED HLA REGION SNPs WITH HLA ALLELES.

**185-P**
HIGH FREQUENCY OF ANTI HLA-DQ7 (DQB1*0301) ANTIBODIES FOUND IN HEALTHY NON-ALLOIMMUNIZED MALES.
Maria Cecilia S. Freitas¹, Nubia Banuelos², Ali Hajeer², Nadim El-Awar², Paul I. Terasaki¹. ¹Terasaki Foundation Laboratory, Los Angeles, CA, USA; ²One Lambda Inc, Los Angeles, CA, USA; ³Department of Pathology and Laboratory Medicine, King Fahad National Guard Hospital, Riyadh, Saudi Arabia.
Abstracts

186-P
THE IL-2 LOW PRODUCTION ALLELE IL2-330(G/T) IS INVOLVED IN SUSCEPTIBILITY TO CLASSIC PARS PLANITIS IN MEXICAN MESTIZOS.
Hilario Flores-A, Carmen Alaez, David Garcia, Luz E. Concha, Lourdes Arellanes, Clara Gorodezky. 1Dept. of Immunology & Immunogenetics, InDRE, Secretary of Health, Mexico City, DF, Mexico; 2Inflammatory Eye Disease Clinic, Asociación para Evitar la Ceguera en México, I A.P. Hospital “Dr. Luis Sánchez Bulnes”, Mexico City, DF, Mexico.

187-P
SNPs OF INFγ+874(A/T) AND IL-6-174(G/T) DO NOT CONTRIBUTE TO THE ETIOLOGY OF PROLIFERATIVE DIABETIC RETINOPATY IN MEXICANS WITH T2D.
David Garcia, Carmen Alaez, Hilario Flores-A, Jans Fromow, Hugo Quiroz, Clara Gorodezky. 1Dept. of Immunology & Immunogenetics, InDRE, Secretary of Health, Mexico City, Mexico; 2Service of Retina, APEC, Mexico City, Mexico.

188-P
GLOBAL MAPS OF HLA A-B-DRB1 HAPLOTYPE FREQUENCIES IN BMDW REGISTRIES AVAILABLE IN A WEB APPLICATION.
Eric P. Williams, Loren Gragert, Martin Maiers. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

189-P
SINGLE PASS VERY HIGH RESOLUTION HLA GENOTYPING BY NEXT GENERATION SEQUENCING WITH THE 454 LIFE SCIENCES GS FLX AND GS JUNIOR.
Bryan N. Hoglund, Cherie L. Holcomb, Priscilla V. Moonsamy, Damian Goodridge, Henry A. Erlich. 1Human Genetics, Roche Molecular Systems, Pleasanton, CA, USA; 2Conexio Genomics, Perth, Australia.

190-P
HLA-B50 POLYMORPHISM IN HEALTHY SAUDIS.
Dunia Jawdat, Balkese Al-Hamad, Mohammed Al-Jumah, Ali H. Hajeer. 1Immunology, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 2Basic Medical Sciences, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 3Immunology, Department of Pathology & Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

191-P
HLA–DPB1 POLYMORPHISM IN NORTH INDIAN POPULATION.
Uma Kangal, Alasdair McWhinnie, Manish Kumar Mourya, Renu Sharma, Bronwen E. Shaw, Alejandro Madrigal, Narinder Kumar Mehra. 1Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India; 2Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom.
Abstracts

192-P
HLA DIVERSITY AMONG A TRIBAL POPULATION FROM WESTERN INDIA.
Uma Kanga1, Deepali Krishan1, Niranjana Mohta2, Paras Singh1, Manish Kumar Mourya1, Rajender Prasad Agarwal2, Narinder Kumar Mehra1. 1Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India; 2Diabetes Care and Research Centre, SP Medical College, Bikaner, India.

193-P
ASSOCIATION OF NATURAL KILLER CELL KIR GENE WITH HEMATOLOGI-
CAL MALIGNANCIES.
Ekaterina G. Khamaganova, Marina V. Suchkova. Dept of Immunotyping, Hematology Research Center, Moscow, Russian Federation.

194-P
TRANSITION TO SBT FOR SOLID ORGAN HLA TYPINGS.
Scott Lake, Nebila Abdulwahab, Adam Schoen, Pat Adams, Nicholas DiPaola. Tissue Typing, The Ohio State University Medical Center, Columbus, OH, USA.

195-P
ALLELES BELONGING TO THE C*07:01/07:06/07:18 GROUP IN THE
KOREAN POPULATION.
Kyung Wha Lee, Young-A. Jung. Hallym Institute for Genome Application, College of Medicine, Hallym University, Anyang, Korea.

196-P
HLA DQB1* IN BLADDER CANCER PATIENTS OF CASTILLA Y LEON (SPAIN).
Javier Garcia1, Alberto J. Leon2, Victoriano J. Leon3, Manuel Urrutia1. 1Servicio de Urologia, Hospital Universitario de Salamanca, Salamanca, Spain; 2Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 3Servicio Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain.

197-P
POLYMORPHISM SER326CYS OF GEN hOGG1 IN PROSTATE CANCER
PATIENTS.
Javier Garcia1, Alberto J. Leon2, Victoriano J. Leon3, Maniuel Urrutia1. 1Servicio de Urologia, Hospital Universitario de Salamanca, Salamanca, Spain; 2Division of Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 3Servicio de Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain.

198-P
HLA GENES AS MARKERS IN SOME RHEUMATOLOGICAL DISEASES.
Alberto J. Leon1, Victoriano J. Leon2, Susana Gomez Castro3, Maria Dolores Sanchez Gonzalez3. 1Division Experimental Therapeutics, Toronto General Research Institute, Toronto, ON, Canada; 2Servicio Analisis Clinicos, Hospital Universitario de Salamanca, Salamanca, Spain; 3Servicio de Reumatologia, Hospital Universitario de Salamanca, Salamanca, Spain.
Abstracts

199-P
OPEN ACCESS IMMUNOGENOMICS AT IMMUNOGENOMICS.ORG.
Steven J. Mack, Jill A. Hollenbach. CHORI, Children’s Hospital Oakland Research Institute, Oakland, CA, USA.

200-P
THE IMPORT AMBIGUITY RESOLUTION TOOL: A FREQUENCY-BASED APPROACH TO RESOLVING ALLELIC AND GENOTYPIC AMBIGUITY IN HLA GENOTYPE DATA.
Steven J. Mack1, Paula A. Guidry2, Nishanth Marthandan3, Thomas Smith3, John Campbell3, Patrick Dunn4, David R. Karp5, Richard M. Single5, Glenys Thomson6, Jeffrey Wiser6, Richard H. Scheuermann2,7, Henry A. Erlich1,8. 1Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA; 2Department of Pathology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA; 3Health Information Systems, Northrop Grumman, Rockville, MD, USA; 4Department of Internal Medicine, UT Southwestern Medical Center at Dallas, Dallas, TX, USA; 5Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA; 6Department of Integrative Biology, University of California, Berkeley, CA, USA; 7Department of Clinical Sciences, UT Southwestern Medical Center at Dallas, Dallas, TX, USA; 8Department of Human Genetics, Roche Molecular Systems, Pleasanton, CA, USA.

201-P
USE OF THE Fluidigm® Access Array™ SYSTEM PROVIDES SIMPLIFIED AMPICON LIBRARY PREPARATION IN NEXT GENERATION SEQUENCING FOR HIGH THROUGHPUT HLA GENOTYPING.
Priscilla V. Moonsamy1, Persia L. Bonella2, Timothy C. Williams2, Cherie L. Holcomb1, Gregory S. Turenchalk3, Lisbeth A. Blake3, Bryan N. Hoglund1, Melinda Rastrou1, Derek A. Daigle3, Birgitta B. Simen4, Damian Goodridge5, Grant Hillman1, Amy Hamilton2, Andrew P. May2, Henry A. Erlich1. 1Human Genetics, Roche Molecular Systems, Inc., Pleasanton, CA, USA; 2Human Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA; 3Research, 454 Life Sciences, a Roche Company, Branford, CT, USA; 4Conexio Genomics, Perth, Australia; 5Research, Fluidigm Corporation, South San Francisco, CA, USA.

202-P
HLA DIVERSITY IN KASHMIRI POPULATION FROM INDIA.
Manish Kumar Mourya1, Uma Kang1, Mir Itikhar Bashir2, Abhishweta Saxena1, Abdul Hamid Zargar2, Narinder Kumar Mehra1. 1Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India; 2Department of Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India.

203-P
DRB3*02:02 INCREASES TYPE 1 DIABETES RISK FOR DR3/DR3 GENOTYPES BUT NOT FOR HIGH-RISK DR3/DR4 GENOTYPES.
Janelle A. Noble1, Shana L. McDevitt1, Ana Maria M. Valdes2. 1Research, Children’s Hospital Oakland Research Institute, Oakland, CA, USA; 2Twin Study Unit, King’s College London, London, United Kingdom.
Abstracts

204-P
DRB1*07:01 INCREASES RISK FOR BACTERIAL VAGINOSIS IN BLACK WOMEN.
Janelle A. Noble1, Jill Hollenbach1, Julie A. Lane1, Jenifer Allsworth2. 1Research, Children’s Hos- pital Oakland Research Institute, Oakland, CA, USA; 2Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

205-P
IMMUNOGENETICS OF COMPLEMENT C4 DEFICIENCIES.
Riitta Paakkanen1,2, Annika Wennerström1, Inka Liesmaa3, Jari Suvi-Lehto4,5, Mikko Seppänen3, Asko Järvinen5, Ville Valtonen3, Markku S. Nieminen4, Juha Sinisalo2, Marja-Liisa Lokki1. 1Haart- man Institute, Transplantation Laboratory, University of Helsinki, Helsinki, Finland; 2Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland; 3Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland; 4Haartman Institute, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; 5Department of Otorhinolaryngology, Helsinki University Central Hospital, Helsinki, Finland.

206-P
ON HLA DNA TYPING BY SSOP: INVESTIGATION OF QC PARAMETERS AND DNA REQUIREMENT FOR ACCURATE ALLELE DISCRIMINATION.
Cindy H. Park1, Kejal Ghiwala1, Sharon Austria1, Sue Tiongko1, Laura Baraian1, Rex Friedlander1, Arvind Menon1, Vijay Sharma1, Manikkam Suthanthiran1,2, Darshana Dadhania1,2. 1IGT, Rogosin Institute, New York, NY, USA; 2Transplantation Medicine, Weill Cornell Medical Center-NYPH, New York, NY, USA.

207-P
FUNCTIONAL IMPLICATIONS OF MHC ASSOCIATIONS IN VITILIGO.
Rajni Rani1, Archana Singh1, Pankaj Sharma2, Hemanta K. Kar2, Vinod K. Sharma2, Manoj K. Tembhre3, Samesh Gupta4, Naresh C. Laddha5, Mitesh Dwivedi6, Rasheedunnisa Begum4, Indian Genome Variation Consortium5, Rajesh S. Gokhale1,5. 1Molecular Immunogenetics Group, National Institute of Immunology (NII), New Delhi, Delhi, India; 2Dermatology, Dr. Ram Manohar Lohia Hospital (RMLH), New Delhi, Delhi, India; 3Dermatology, All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, India; 4Department of Biochemistry, Faculty of Science, Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India; 5Systems Biology, Institute of Genomics and Integrative Biology (CSIR), Delhi, India.

208-P
AUTOMATED DETECTION OF DELETION SEQUENCE IN HLA-DQA1.
Joel Shi, Dina Berchanskiy, Tina Agostini, David Dinauer, Inta Veldre. RnD, Life Technologies, Brown Deer, WI, USA.

209-P
PREDICTING GROUP SPECIFIC SEQUENCE PRIMER USAGE BY DATA MI- NING METHOD.
Joel Shi, Dina Berchanskiy, Yuanping Xu, Tina Agostini, David Dinauer. RnD, Life Technologies, Brown Deer, WI, USA.
Abstracts

210-P
HLA VARIATION AND RISK OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA.
Darif Krasnow1, Christine Skibola2, Margaret Vinson1, Martha Ladner1, Elizabeth Trachtenberg1.
1Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA; 2Division of Environmental Health Sciences, School of Public Health, UC Berkeley, Berkeley, CA, USA.

211-P
FREQUENCIES OF MICA ALLELES IN PATIENTS WITH MULTI AND PAUCIBIL- LARY LEPROSY FROM THE SOUTH OF BRAZIL.
Willian S. Sacramento, Luciana R. Jarduli, Priscila S. Mazini, Danilo A.S. Franceschi, Fabiano C. de Melo, Marco A. Braga, Ana M. Sell, Luiza T. Tsuneto, Jeane E.L. Visentainer. Departamento de Ciências Básicas da Saúde, Universidade Estadual de Maringá, Maringá, Paraná, Brazil.

212-P
ALLELE AND HAPLOTYPE POLYMORPHISM OF HLA-A, B, DRB1 AND C4A/ C4B LOCI IN FINNISH POPULATION.
Annika Wennerstrom1, Katja T. Eronen1, Hanna Vauhkonen1, Mikko Seppanen2, Anil Palikhe1, Marja-Liisa Lokki1. 1Haartman Institute, Transplantation Laboratory, Helsinki, Finland; 2Department of Medicine, Immunodeficiency Unit, Division of Infectious Diseases, Helsinki, Finland.

213-P
PRELIMINARY STUDY ON SCREENING OF HLA ANTIBODY AND SPECIFICITY ANALYSIS FOR GUANGZHOU BLOOD DONORS.
Xin Ye, Wenjie Xia, Jing Deng, Xiuzhang Xu, Yangkai Chen. Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, China.

214-P
THE DISTRIBUTION OF HLA-A,B,DRB1 ALLELES AND HAPLOTYPES IN CANTONESE.
Xin Ye, Haoqian Ding, Yangkai Chen, Yuan Shao, Wenjie Xia. Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, China.

215-P
SHOULD CONFIRMATORY HLA TYPING BE MANDATORY?
Charlene Breitenbach2, Robert A. Bray1, Howard M. Gebel1. 1Histocompatibility Laboratory, Henri-co Doctors’ Hospital, Richmond, VA, USA; 2Pathology, Emory University, Atlanta, GA, USA.
Abstracts

216-P
DETECTION OF DE NOVO ANTIBODIES TO ALL MISMATCHED DONOR HLA ANTIGENS INCLUDING ALLELE LEVEL ANTIBODIES DEVELOPED IN A KIDNEY RECIPIENT.
Xiangmin Nie1,2, Angelcia DeOliveira1, Bobbie Holeman1, Candace Young1, Dong-Feng Chen1.
1Clinical Transplantation Immunology Lab, Duke University Medical Center, Durham, NC, USA; 2HLA Lab, Blood Center of Shandong Province, Jinan, Shandong, China.

217-P
A CASE OF MISTAKEN IDENTITY: HAMAs RESULTING IN A FALSE POSITIVE B CELL FLOWCYTOMETRY CROSSMATCH.
Darshana Dadhania1,2, Kelly Skill1, Rex Friedlander1, Arvind Menon1, Manikkam Suthanthiran1,2, Vijay Sharma1. 1IGT, Rogosin Institute, New York, NY, USA; 2Transplantation Medicine, Weill Cornell Medical Center - NYPH, New York, NY, USA.

218-P
MONITORING DONOR-SPECIFIC ANTIBODY STRENGTH BY LUMINEX SINGLE ANTIGEN BEAD ASSAY AIDS KIDNEY POST-TRANSPLANT CLINICAL MANAGEMENT: TWO CASE REPORTS.
Zeying Du1, Bozena Labuda2, Andres Jaramillo2, Sujata Gaitonde1. 1Department of Pathology, University of Illinois Medical Center, Chicago, IL, USA; 2Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA.

219-P
LIVING DONOR LUNG TRANSPLANT: A REJECTION CASE STUDY.
Anne Halpin, Roland Nador, Luis Hidalgo, Patricia Campbell. Histocompatibility Laboratory, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada.

220-P
CASE STUDY: POSITIVE T-CELL FLOW CROSSMATCH (TFXM)/NEGATIVE B-CELL FLOW CROSSMATCH (BFXM) CAN BE MEDIATED BY A CLASS I ANTIBODY.
June Inlow, Paula Steller, Aisha Eltayeb, Annette Rearick, Matt Kott, Patrick Adams, Nicholas DiPaola, Ronald Pelletier. Clinical Histocompatibility Laboratory, The Ohio State University Medical Center, Columbus, OH, USA.

221-P
FLOW CROSSMATCH BIMODAL DISTRIBUTION FOR T CELL TREATED WITH PRONASE.
Ricardo Lopez1, Saber J. Al-Zahrani1, Mohammed I. Awaji1, Abdulrahman A. Housawi2, Mohammed Saghier2, Faisal M. Khan3,4,5, Noureddine Berka3,4. 1Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2Multi-Organ Transplant Center, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 3Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada; 4Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; 5Paediatrics, University of Calgary, Calgary, Canada.
Abstracts

222-P
ONE EXAMPLE OF WHY MFI LEVELS SHOULDN’T BE REPORTED.
Donna P. Lucas, Julie A. Houp, June A. Jones, Andrea A. Zachary, Mary S. Leffell. Medicine, Johns Hopkins University, Baltimore, MD, USA.

223-P
THE IMPORTANCE OF IDENTIFYING WEAK DSA AT THE TIME OF TRANSPLANT IN THE FACE OF A NEGATIVE CROSSMATCH.
Tracy T. McRacken¹, Robert A. Bray², Howard M. Gebel², Monica S. Stephens¹, Yury Kalmanovich¹.¹ Transplant Immunology Laboratory, Sentara Norfolk General Hospital, Norfolk, Virginia, USA; ²Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, USA.

224-P
A RARE DRB1 ALLELE IDENTIFIED IN A CORD BLOOD UNIT AND THE MOTHER.
Lucie Richard, Élise Trudel, Diane Fournier, Diane Roy, Marie-Claire Chevrier. Stem Cell and Reference Laboratory, Hema-Quebec, Saint-Laurent, QC, Canada.

225-P
A REPRODUCIBLE FALSE POSITIVE SCREEN FOR HLA ANTIBODIES BY ELISA.
Benjamin A. Schwarz¹, Todd L. Astor², Donna Fitzpatrick¹, Susan L. Saidman¹.¹ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA; ²Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

226-P
HYPERACUTE GRAFT LOSS FROM ANTI-PHOSPHOLIPID ANTIBODY (aPL) DESPITE ANTICOAGULATION THERAPY.
Brian Susskind¹, Smita Vaidya², Dawn Wagenknecht³, John McIntyre³, Judith Baker¹, Daniel Savino¹, Nicholas Onaca⁴, Larry Melton⁴.¹ Pathology, Baylor University Medical Center, Dallas, TX, USA; ²Tissue Antigen Lab, U Texas Medical Branch, Galveston, TX, USA; ³HLA-Vascular Biology Laboratory, Franciscan St. Francis Health, Indianapolis, IN, USA; ⁴Annette C and Harold C Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, USA.

227-P
HYPERACUTE LIVER ALLOGRAFT LOSS FROM ANTI-PHOSPHOLIPID ANTIBODIES (aPL).
Jacqueline G. O’Leary¹, Brian Susskind², Daniel Savino², John McIntyre³, Dawn Wagenknecht³, Smita Vaidya⁴, Judith E. Baker², Goran B. Klintmalm⁴.¹ Annette C and Harold C Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, USA; ²Pathology, Baylor University Medical Center, Dallas, TX, USA; ³HLA-Vascular Biology Laboratory, Franciscan St. Francis Health, Indianapolis, IN, USA; ⁴Tissue Antigen Lab, U. TX Medical Branch, Galveston, TX, USA.
Abstracts

228-P
IS C1Q READY FOR PRIME TIME?
Sharon E. Zeeben1, Luz Stamm1, Kim Larlee1, Noureddine Berka1,2. 1Tissue Typing, Calgary Laboratory Services, Calgary, AB, Canada; 2Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.

229-P
DIFFERENCE IN RESPONSE TO NEW ANTIGEN IN AGED COMPARED TO YOUNG ANIMALS IN A MURINE MODEL.
Benita K. Book1, Erin K. Ward1, Mark A. Volz1, George J. Eckert2, Eric A. Wiebke1, Mark D. Pescovitz1. 1Surgery, Indiana University School of Med, Indianapolis, IN, USA; 2Biostatistics, Indiana University School of Med, Indianapolis, IN, USA; 3Indianapolis, IN, USA.

230-P
IMPROVING SINGLE ANTIGEN ASSAY REPRODUCIBILITY USING A LINEAR REGRESSION MODEL.
Robert W. Bresler, Judith C. Knakewicz, Judith M. Wysocki, Gregory S. Stempfle, Kamal A. Abu-arquob, Cynthia A. Schall, Daniel S. Ramon. Department of Pathology, University of Michigan, Ann Arbor, MI, USA.

231-P
ELIMINATING THE RED MENACE.
Sharlie B. Brown, David F. Kiger, Elaine F. O’Shields, Michael D. Gautreaux. HLA/Immunogenetics Laboratory, Wake Forest School of Medicine, Winston-Salem, NC, USA.

232-P
VALIDATION OF A CYTOMETRIC BEAD ARRAY (CBA) ASSAY TO DETECT ANTI-ERYTHROPOIESIS STIMULATING AGENT (ESA) ANTIBODIES TO SUPPORT DIAGNOSTIC TESTING AND PHARMACOVIGILANCE.
Kortney Davis, Troy Barger, Daniel Mytych, Steven Swanson, Theresa Goletz, Deborah Wrona. Clinical Immunology, Amgen, Seattle, WA, USA.

233-P
POSITIVE CONTROL BEADS IN SINGLE ANTIGEN BEAD ASSAYS: NOT AS SMART AS WE HOPED THEY WOULD BE.
Newson Ly, Anne Halpin, Patricia Campbell, Luis Hidalgo. Histocompatibility Laboratory, University of Alberta Hospital, Edmonton, AB, Canada.
Abstracts

234-P
IDAWG 16th IHIW PROJECT: IMMUNOGENOMIC DATA MANAGEMENT METHODS.
Steven J. Mack, Jill A. Hollenbach. Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, USA.

235-P
COMPARISON OF DNA QUANTITY AND QUALITY FROM DIFFERENT DECEASED DONOR SOURCES ISOLATED BY AN AUTOMATIC SYSTEM.
Elaine F. O’Shields¹, David F. Kiger¹, Cynthia C. Petty², Jeff Franz², Michael D. Gautreaux¹. ¹General Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA; ²North American Sales, Promega Corporation, Madison, WI, USA.

236-P
CLASS II TRANSACTIVATOR (CIITA) A IS A KEY REGULATOR OF THE SEMAPHORIN-RECEPTOR SYSTEM.
Laura Schlahsa, Anja Battermann, Britta Eiz-Vesper, Rainer Blasczyk, Constanca Figueiredo. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

237-P
ESTABLISHING A REFERENCE RANGE FOR CONTROL BEADS IN SINGLE ANTIGEN ANTIBODY ASSAYS.
Kirsten Tronsgard, Anne Halpin, Patricia Campbell. Histocompatibility Laboratory, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada.

238-P
INFERENCE OF GOOD AND BAD HLA LIGANDS THROUGH MOLECULAR DYNAMICS APPROACH.

239-P
IMPLEMENTATION OF AN ELECTRONIC DATA MANAGEMENT SYSTEM IN THE TRANSPLANT IMMUNOLOGY AND IMMUNOGENETICS LABORATORY AT THE UNIVERSITY OF CHICAGO.
Andrea A. Zimmerman, Laura K. Spruit, Rebecca L. Upchurch, Walter F. Herczyk, Jerome G. Weidner, Susana R. Marino. Transplant Immunology and Immunogenetics Laboratory, University of Chicago Medical Center, Chicago, IL, USA.
Future Annual Meetings

38th Annual Meeting
October 8 -12, 2012
Sheraton Puerto Rico Convention Center Hotel
San Juan, Puerto Rico

39th Annual Meeting
November 18 – 22, 2013
Sheraton Chicago Hotel and Towers
Chicago, Illinois

40th Annual Meeting
October 20 – 24, 2014
Sheraton Denver Downtown Hotel
Denver, Colorado
Final Program Printing Supported By

GEN-PROBE